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1 Abstract 
High Pathogenic Avian Influenza (HPAI) viruses, such as H7N9 and H5N1 HPAI, have a 
very large effect on poultry production and there is a need for new strategies to deal 
with these infections. The characterization of antiviral immune pathways is essential for 
understanding host-pathogen mechanisms to underpin improved therapies for both 
human and livestock use. The interferon (IFN) pathway stimulates the expression of a 
myriad of interferon stimulated genes (ISGs) that impact viral replication. This study 
aimed to characterize the chicken type III IFN response, its receptor complex and its 
downstream mediator.  
The induction of type III IFN in comparison to type I IFNs was examined in chicken 
splenocytes stimulated with TLR agonists and chicken IFNs. The induction of type I and 
type III IFNs by PIC and LPS was similar but IFN and ISG induction kinetics differed in 
response to IFNα and IFNλ with IFNα inducing a more rapid induction. Furthermore, age 
and sex dependent differences in the induction of type I and type III IFNs were 
identified, while females had higher levels of type I IFNs as immature and mature birds, 
immature males had a higher IFNλ response. 
The IFNλR complex is composed of two receptor chains, the IFNλ receptor 1 (IFNλR1) 
and Interleukin 10 receptor 2 (IL-10R2), which utilizes the Janus kinase (JAK) and Signal 
transducer and activator of transcription (STAT) pathway for signaling. A chicken IFNλR1 
gene was identified, which showed conserved sequence and synteny with its human 
counterpart. Selective siRNA mediated knockdown of either chain reduced IFNλ 
mediated ISG expression and STAT activation, while selective JAK1 inhibition blocked the 
IFNλ mediated ISG upregulation. This points towards a conserved IFNλR/JAK/STAT/ISG 
pathway in chickens. 
The interferon-induced protein with tetratricopeptide (IFIT) repeats 5 (IFIT5) is an ISG 
that has been shown to be important in the antiviral response in mammals. A single IFIT 
was identified in chicken which showed synteny with the human IFIT genes and encoded 
a 470 amino acid protein with strong conservation to mammalian IFITs especially IFIT5. It 
was induced in chicken splenocytes by IFNα, IFNλ and TLR ligands ex vivo, in the lungs of 
chickens following infection with a highly pathogenic avian influenza virus (HPAI). This 
highlighted the conserved role of chicken IFIT5 in the response to viral infections like 
HPAI. 
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2 List of Abbreviations 
AA  amino acids 
aa/s amino acid substitutions per site 
AI avian Influenza 
ANOVA analysis of variance 
APC antigen presenting cells 
bp base pair 
CHD cytokine receptor homology domain  
CHO  Chine Hamster ovary cells 
CO2  carbon dioxide 
CRF2 class II cytokine receptor family  
CSF colony-stimulating factor 
CSIRO Commonwealth Scientific Industrial Research Organisation  
DMSO dimethyl sulfoxide 
dsDNA double stranded DNA 
dsRNA double stranded RNA 
E.coli  Escherichia coli 
EID50 50% egg infectious dose  
ELISA enzyme-linked immunosorbent assay 
EMSA electrophoretic mobility shift assay 
ERK extracellular signal regulated kinase 
HA Hemagglutination Assay 
HBV Hepatitis B  
HCV) Hepatitis C 
HPAI highly Pathogenic Avian Influenza 
IBDV infectious bursal disease virus 
IBV infectious bronchitis virus 
IFIT  interferon-induced protein with tetratricopeptide repeats  
IFN  interferon 
IFNα  interferon alpha 
IFNαR1 interferon alpha receptor chain 1 
IFNαR2 interferon alpha receptor chain 2 
IFNγR1 interferon gamma receptor chain 1 
IFNγR2 interferon gamma receptor chain 2 
IFNλ  interferon lambda 
IFNλR  interferon lambda receptor 
IFNλR1 interferon lambda receptor chain 1 
IL interleukin 
IL-10R2 interleukin 10 receptor chain 2 
IRF-9 IFN regulatory factor-9  
ISGF3 IFN stimulated gene factor 3 
ISGs IFN stimulated genes 
ISREs IFN stimulated response elements (ISREs)  
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JAK Janus kinase 
JNK c-Jun N terminal kinases 
LPS  lipopolysaccharides 
LSD least significant difference 
MAPK mitogen-activated protein kinase 
MDA-5 melanoma differentiation-associated gene 5  
MDV Marek’s disease virus  
mRNA messenger RNA 
MX1 Myxovirus resistance gene 1 (Mx1 
NA neuroaminidase 
NDV Newcastle disease virus (NDV)  
PAMPs pathogen associated molecular patterns 
PBMC peripheral blood monocytes 
PCR polymerase chain reaction 
PIC  poly I:C 
PKR IFN-induced double-stranded RNA dependent protein kinase 
PRR pattern recognition receptor 
RIG-I retinoic acid-inducible gene-I)  
RT-PCR real-time polymerase chain reaction 
SEM standard error of the mean  
SFV Semliki Forest virus (SFV)  
SNP single nucleotide polymorphism 
ssRNA single stranded RNA 
STAT  signal transducer and activator of transcription 
TLR  Toll-like receptor 
TNF tumor necrosis factor  
TYK2 tyrosine kinase 2  
Viperin virus inhibitory protein, endoplasmic reticulum associated, interferon inducible  
VSV vesicular stomatitis virus  
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4 Introduction 
4.1 Avian influenza 
Influenza A viruses are members of the Orthomyxoviridae family being lipid enveloped, 
negative-sense, single-stranded segmented RNA viruses, with eight segments encoding ten 
proteins 1,2. Protruding from the enveloped surface are two distinct glycoproteins, the 
hemagglutinin (HA) and the neuraminidase (NA) on which subtypes and antigens are 
classified 3,4 (Figure 4-1). Influenza is capable of infecting a range of hosts including but not 
limited to humans, dogs, horses, pigs, ferrets, cats and a wide variety of domesticated and 
wild birds 5-12. It is believed that wild aquatic birds act as a reservoir for influenza A viruses, 
since virtually all HA and NA subtypes have been isolated from that source 13. The exceptions 
are the recently discovered subtypes H17 and H18 that seem to be limited to bats 14,15 
(Figure 4-2). This suggests that spill-over hosts, like domesticated poultry and humans, will 
remain at risk due to the difficulties of eradicating a pathogen in a wild population.  
There are two major mechanisms influencing viral diversification. Antigenic drift (Figure 4-3) 
describes the mechanism of generating seasonal influenza virus, where point mutations in 
the viral genome change the antigenic profile of the virus leading to immune evasion 16,17. 
Antigenic shift (Figure 4-3) describes the rearrangement of the segmented genome when 
more than one strain infects one cell which forms a new virus with often unique properties 
18,19. This is thought to occur particularly in pigs, which can be infected by both avian and 
human virus strains, giving rise to new highly pathogenic influenza variants 20. The selective 
pressure of the host immune system plays a key role in both antigenic drift and shift 21,22. 
Infectivity of influenza virus in the host is influenced by the type of receptor the virus can 
bind 23. The HA subtypes of avian influenza (AI) viruses, such as the H5 and H7 subtypes, are 
thought to preferentially attach to the α 2,3-linked sialic acid receptors present on the 
respiratory epithelium and intestinal tract tissue of many avian and terrestrial bird species 24 
while HA subtypes adapted to humans preferentially bind the α 2,6-linked sialic acid 
receptors 25. However, there are exceptions to this, with single amino acid substitutions at 
the receptor binding site of the HA molecule enough to allow HPAI H5N1 viruses to 
recognize the human α 2,6-linked sialic acid receptor on the surface of human respiratory 
epithelial cells and thereby assist in cross-species transmission 26. It has similarly been shown 
in the recent H7N9 outbreak in China that the human virus isolates possessed two mutations 
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associated with increased α 2,6-linked sialic acid binding that could account for their human 
pathogenicity 27. Therefore, both antigenic shift and drift can also influence host specificity.  
AIs can cause significant mortality and morbidity in humans. Since 2003 851 human cases of 
H5N1 were reported, which led to 450 deaths 28. More recently the H7N9 LPAI, which caused 
no death in chickens 29, led to severe symptoms and even death in humans 27. Until now a 
total of 781 laboratory confirmed cases have been reported causing 313 deaths 30. In 2014 a 
new H5 virus emerged, subtyped as an H5N6, which caused 14 confirmed cases and 6 deaths 
28,31. Evidently the AI viruses are still re-assorting and are likely to cause more mortality and 
morbidity since they have now become endemic in a number of countries and pose a serious 
risk of becoming a new pandemic strain 31-33. 
Apart from the human cases, HPAI strains have killed millions of poultry worldwide directly 
and indirectly, since containment of the outbreaks has necessitated culling of additional 
birds. The impact of HPAI strains on the poultry industry has been substantial with the 
economic loss has been numbered in the billions (USD) 34,35. Transmission of AI from poultry 
to humans usually occurs by close association 27,36. Therefore, an AI virus with the ability to 
spread easily between host species poses a serious risk and could be a potential influenza 
pandemic virus candidate 37.  
 
Influenza viruses are negative-sense single-stranded RNA viruses. Their genome consists of 
eight RNA segments that encode 10 proteins, which are encapsulated by matrix proteins and 
surrounded by a host-derived lipid envelope from which the glycoproteins hemagglutinin 
and neuraminidase protrude.  
Figure 4-1 Schematic structure of influenza virus 
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Figure 4-2 Host range and infection cycle of influenza virus 
Water fowl, such as ducks, are thought to be the natural reservoir for influenza virus. 
Through the fecal/oral route they infect a range of domesticated animals like horses, pigs 
and chickens. The virus can then reach the human population by transmission via chickens or 
pigs. In contrast, the newly discovered H17 and H18 subtypes seem to be limited to bats.  
 
 
Figure 4-3 Antigenic drift of influenza virus 
Seasonal influenza viruses typically acquire mutations through their error prone viral RNA 
polymerase. These mutations can alter antigenicity and enable the virus to escape the 
immune system. 
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Figure 4-4 Antigenic shift of influenza virus 
Different strains of influenza that infect the same cell can rearrange their segmented 
genomes, which can lead new gene combinations not previously encountered by the host 
immune system, potentially leading to new pandemic viruses. The pig is thought to be the 
ideal ‘mixing vessel’ since avian as well as human pathogenic influenza strains can infect it. 
 
4.2 Host immune response to viral infections 
The mammalian immune response to virus infections is well characterized. During viral 
invasion, innate immune recognition is mediated by a series of germ line encoded receptors, 
the pathogen recognition receptors (PRR), which detect conserved pathogen associated 
molecular patterns (PAMPs) 38-40. One of the most prominent families of PRR are the Toll-like 
receptors (TLR) 41. Up to thirteen conserved TLRs have been found in mammals that serve 
distinct functions in PAMP recognition and subsequent immune responses, although 
variation between species exist in the number of functional TLRs 42,43. TLRs induce the 
expression of genes involved in both direct cellular defence and the mobilization of a wider 
immune response 38,44. Infection with viral pathogens may be sensed through TLRs 2 and 4 
that detect viral glycoproteins on the cell surface or through recognition of dsRNA through 
TLRs 3,7, 8 and 9 located in the endosome 45-51. In addition to the TLRs, intracellular sensors 
such as retinoic acid-inducible gene-I (RIG-I) and melanoma differentiation-associated gene 5 
(MDA-5) are involved in the cytosolic recognition of foreign nucleic acids 52. PAMP 
recognition leads to activation of many cell types, such as phagocytes and macrophages and 
the expression of a number of genes including those encoding cytokines 53,54. Cytokines are 
soluble, low molecular weight polypeptides and glycopeptides that interact with a 
multicomponent transmembrane receptor complex and activate intracellular signal 
transduction pathways that induce anti-viral genes as well as others that control the 
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complex interplay between various cell types involved in the immune response 55-57. 
Cytokines represent a large family of signaling molecules, including the interferons (IFN), 
interleukins (IL), colony-stimulating factors (CSF), transforming growth factors (TGF) and 
tumor necrosis factors (TNF), each of which consists of multiple members 58. However, the 
IFNs produced in the early stages of viral infection are of special interest since they play a 
crucial role in the broad spectrum cellular defence against the spread of virus 59 (Figure 4-5). 
 
The antiviral actions of the type I/III interferon systems have been extensively studied in 
mammals. Upon sensing foreign nucleic acids host Toll-like receptors activate signals that 
induce the transcription of IFN genes, the products of which are secreted by the cell and 
serve to amplify the signal in an autocrine and/or paracrine manner. This is achieved by 
binding to cognate receptors that relay a signal via downstream signal pathways into the cell 
nucleus, which leads to the expression of ISGs. These genes encode proteins that block viral 
infection, growth and spread in a multitude of ways. 
 
4.3 IFNs 
IFNs were discovered by Isaacs and Lindenmann while studying influenza virus. They 
described the first IFN as a substance that was able to interfere with the ability of the virus 
to infect cells and thus coined the term “interferon” 60. It is now recognized that there are in 
fact several IFNs that are collectively crucial for defence against pathogens, contributing to 
the induction and regulation of both innate and adaptive antiviral mechanisms 61-63. Three 
distinct IFN families have been identified in vertebrate species. The families are defined by 
their use of specific receptor complexes, termed type I, II and III. These are distinguished by 
their distinctive signaling pathways and patterns of gene induction, although there is 
considerable overlap in these features between families 64-66. All three IFN families are 
Figure 4-5 The IFN-mediated antiviral response 
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important for an effective immune response but only type I and III are directly induced via 
the PRR pathway 59. This suggests that they play a critical role in containing pathogens, 
providing the host with the means to survive otherwise lethal infections by delaying spread 
of the pathogen and enabling the adaptive immune system to mount an efficient response 
67. 
4.3.1 Type I IFN 
Type I IFNs consist of at least 8 subclasses IFNα, IFNβ, IFNε, IFNκ, IFNω, IFNτ, IFNδ and IFNζ. 
The first 5 are found in humans with 13 subtypes of IFNα but only a single IFNβ, IFNε, IFNκ 
and IFNω 68,69. The other subclasses of type I IFNs have so far only been identified in 
particular species: IFNτ in ruminants 70, IFNδ in pigs 71 and IFNζ in mice 72. 
Following induction by viral infection, type I IFNs can act in both a paracrine and autocrine 
manner 73,74. Of the type I IFNs, IFNα and IFNβ are well characterized, displaying potent 
antiviral activities. A broad range of cells can produce IFNα and IFNβ rapidly during the early 
stages of infection in response to the recognition of viral (and bacterial) products via PRRs 
61,75,76 . In turn IFNs stimulate the expression of more than 300 genes that are called IFN 
stimulated genes (ISGs) many of which encode antiviral proteins that can collectively 
interfere with various stages of the viral life cycle 77-79. This early antiviral response is critical 
to limit the spread of viruses and facilitate onset of the adaptive immune response 80. Type I 
IFNs up-regulate the expression of the major immune histocompatibility complex I (MHC I) 
expression on many cells 81 as well as co-stimulatory molecules on antigen presenting cells 
(APC) 82 , enhance natural killer cell (NK) cytotoxicity, proliferation and memory functions 83-
85 , induce differentiation of monocytes to dendritic cells (DC) 86, contribute to DC activation 
and priming abilities 87, augment the differentiation of T helper (Th) cells 88-90, modulate 
antibody production 91 and induce apoptosis of infected cells 92,93. 
The anti-viral, immune stimulating and anti-proliferative properties of IFNs have made them 
attractive molecules as potential therapeutics for a variety of diseases 93,94. Recombinant 
IFNα was the first approved bio-therapeutic and has been successfully used in the treatment 
of chronic hepatitis B (HBV) and hepatitis C (HCV) infections, where it leads to reduced viral 
loads and decreased incidence of liver cirrhosis and hepatocellular carcinomas 95,96. Type I 
IFNs have also regularly been used in clinics as anti-cancer treatments, such as hairy cell 
leukaemia, Kaposi’s sarcoma, chronic myelogenous leukaemia and metastatic malignant 
melanoma 97-100. Likewise IFNβ forms a crucial part of long-term treatment for relapsing 
forms of multiple sclerosis 101. Combination therapy of IFNα with anti-viral drugs like 
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ribavirin, can improve the treatment efficiency, although clinical drug resistance to IFNα has 
arisen in the setting of HCV infection 102,103. The successful use of IFN alone and in 
combination to treat viral infections has been demonstrated experimentally both in vitro 
and in vivo 104-106. However, type I IFNs represent a two-sided sword since they can also 
induce severe adverse effects ranging from diarrhoea, fatigue and depression to flu-like 
symptoms and hematologic toxicity 107,108.  
4.3.2 Type II IFN 
Only one type II IFN has been identified, IFNγ, which exists as a single gene in mammals and 
birds 109,110. This is a pro-inflammatory cytokine that has an essential role in the activation of 
host defence against intracellular pathogens, representing a hallmark cytokine of Th1 cells 
111,112. In contrast to the type I and III IFNs, type II IFN is only produced by cells of the 
immune system such as NK cells, macrophages, dendritic cells and T cells 113,114. IFNγ has 
similar actions to other IFNs in certain ways but it also has unique properties. For example, it 
is the only IFN that can enhance MHC class II expression 81,115 and is involved in the 
regulation of nitric oxide production and the promotion of Th1 differentiation 116,117. 
4.3.3 Type III IFN 
Type III IFNs were discovered in 2003 through computational analysis of the human genome, 
which identified three distinct proteins 118,119. These were placed phylogenetically between 
type I IFNs and IL-10 related cytokines 120, leading to them being given alternate names. 
Sheppard and colleagues designated them IL-28A, IL-28B and IL-29 while others classified 
them as type III IFNs, IFNλ1 (IL-29), IFNλ2 (IL-28A) and IFNλ3 (IL-28B) with the latter names 
now taking precedence 118. These IFNs share 15-19% amino acid (aa) homology with the type 
I IFNs but only 11-13% aa homology with IL-10, although their intron-exon structure 
resembles those of IL-10 and IL-10-related cytokines, while the crystal structure of IFNλ is 
structurally closest to the IL-10-related IL-22 118,119,121,122. The IFNλ genes are located in 
closely positioned clusters on human chromosome 19 and mouse chromosome 7, 
respectively 118,119,123. In the mouse only two of the three IFNλ genes are considered 
functional 123,124 ,whereas a fourth IFNλ gene has been discovered in humans 120,125. Due to 
their antiviral and anti-proliferative attributes, type III IFNs have also been used in viral 126 
and cancer 127 treatment. 
4.3.4 Expression and regulation 
Co-induction of type I and III IFNs in response to a range of viral and bacterial components 
and TRL agonists has been reported in various in vitro and in vivo settings 64,119,128,129. While 
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both IFN families can be expressed by almost all cell types, the plasmacytoid DC (pDC) 
lineage appears to be the greatest producers of both IFNs in vitro 120,130,131. As mentioned 
earlier, expression of IFNs is triggered by PRRs, including the constitutively-expressed IFN 
regulatory factor (IRF) 3 and the IFN-induced IRF7 132,133. Many RNA viruses potently induce 
IFNλ expression including influenza A virus 130,134, Sindbis virus (SINV) and VSV 118. 
Furthermore, stimulation with ligands for TLR3, TLR4 and TLR9 significantly increased IFNλ 
expression, whereas agonists for TLR7/8 were only weak inducers 130,134-136. It has recently 
been demonstrated that murine macrophages express high levels of type I IFN mRNA but 
not type III IFN mRNA after herpes simplex virus (HSV) infection 135 and that influenza virus 
infection of human alveolar type II cells elicted high levels of IFNλ but not IFNβ 137. 
Characterization of the human type III IFN promoters has revealed the presence of IRF and 
nuclear factor (NF)-κB binding sites 138. IFNλ1 expression exhibited an IRF-3 dependence 
similar to that of IFNβ whereas IFNλ2/3 expression was controlled by IRF-7 similar to IFNα 
139,140. In addition, the NFκB sites in the promoter region of IFNλ1 were shown to be critical in 
DCs, suggesting that NFκB is a key regulator in these cells 141 and providing further evidence 
that the IFN induction pathways of type I and III IFNs differ. This indicates that more work is 
needed to fully understand the regulation of IFNλ. 
4.3.5 Antiviral actions of IFNλ 
IFNs can modulate the immune system, but can also directly interfere with the infection 
cycle of viruses 142, which has seen IFNs successfully used in a variety of antiviral treatments 
102,143,144. The characterization of IFNλ has largely focused on its antiviral role in the course of 
infection, where it displays activities reminiscent of type I IFN. Antiviral assays together with 
gene expression studies have demonstrated that IFNλ induces an antiviral state, with a large 
number of antiviral genes stimulated 137,145, which are mostly identical to those up-regulated 
upon type I IFN stimulation 146. This could point towards redundancy of the immune system 
that could play a critical role in host survival, as many pathogens have developed 
mechanisms to evade or inhibit specific aspects of the host immune response 147. However, 
differences in type I and type III activity can be observed. For example, studies have 
suggested IFNλ antiviral activity was weaker than type I IFNs, with higher concentrations 
required to achieve equivalent induction of antiviral genes 128,129. In addition, the pre-
treatment of cells with IFNλ before viral challenge can lead to reduced viral replication, as is 
also seen with IFNα pre-treatment. In contrast, IFNλ treatment post infection had no effect 
whereas IFNα was still able to inhibit virus replication to some extent 148. A recent study also 
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found that rhinovirus infection of bronchial epithelial cells in vitro induced IFNλ mRNA and 
protein expression more strongly at all time points measured, compared to IFNα, which 
appeared early, and IFNβ, which was induced at later time points 149. Other studies have 
shown that type III IFNs play a critical role in the control of rotavirus. Mice lacking functional 
IFNλ but competent for type I IFN could not control infection via the oral route, while 
administration of type III but not type I IFNs could induce an antiviral state in intestinal 
epithelial cells, providing evidence that this system is independent of type I IFNs 128. Type III 
IFNs have also been shown to have a modulatory effect on the immune system. IFNλ has 
been shown to decrease IL-4, IL-5 and IL-13 production 150, thereby promoting a Th1 rather 
than Th2 response 150,151 in vitro. 
Type III IFNs may provide an alternative therapeutic avenue for the treatment of virus 
infections such as hepatitis C in instances of type I IFN resistance 152,153. Indeed IFNλ has been 
used in combination with ribavirin to control HCV infections with promising results 154. There 
is thus potential for using different drug/IFN combinations, which could result in a further 
anti-viral synergy while decreasing the dose, diminishing side effects and reducing potential 
resistant virus isolates from developing 155,156. Whilst IFNλ displays similar anti-viral and anti-
proliferative activities to type I IFNs their respective outcomes differ in magnitude 146,152. 
Thus, IFNλ may also elicit reduced adverse side effects that are associated with type I IFN 
therapy 157,158. For example IFNλ was found to activate ISGs to a much lower extent in brain 
cells, suggesting that type III IFN therapy might lessen the neuropsychiatric effects 
associated with type I IFN therapies 136,159.  
4.3.6 Apoptosis and anti-proliferative actions of IFNλ 
Type III IFNs have been shown to exert anti-proliferative and pro-apoptotic effects in the 
human keratinocyte cell line (HaCaT) as well as suppress tumor growth and induce apoptosis 
in human glioblastoma, neuroendocrine, lung carcinoma and fibrosarcoma cells in vitro as 
well as in melanoma, fibrosarcoma and colon cancer in vivo and in some cases the ability to 
induce apoptosis was shown to surpass that of IFNα 152,160-162. However, the anti-proliferative 
and pro-apoptotic actions appear independent, since IFNλ decreased cell proliferation of 
intestinal carcinoma cells but did not induce apoptosis 163. Moreover, when responsive cells 
were treated with IFNλ and IFNα they showed a greater apoptotic effect than the respective 
single treatments 160. This suggests a broad therapeutic potential for type III IFNs in 
combination with type I IFNs. However, further investigation is required to fully understand 
how type III IFNs might be used for cancer treatment.  
22 
 
4.4 Class II cytokine receptors 
Members of the Class II cytokine receptor family (CRF2) are single pass transmembrane 
proteins defined by structural similarities in the extracellular domain, which includes the 
cytokine receptor homology domain (CHD) consisting of two tandem fibronectin type III 
repeats that is involved in ligand binding, and intracellular sequences164. They are 
distinguished from Class I cytokine receptors by differences in key amino acids in the CHD, 
notably alternative conserved cysteine residues and the absence of the hallmark WSxWS 
motif 164. CRF2 chains combine to form heterodimeric receptor complexes. The ligands of 
CRF2 bind with high affinity to the R1/Rα chain, which characteristically has a large 
intracellular domain. However, binding of the ligand to the R1 chain is not enough to initiate 
signaling, which requires recruitment of an R2/Rβ chain that has a smaller intracellular 
region and lower ligand affinity. This trimeric complex then initiates specific intracellular 
signaling cascades 164. This family is composed of 12 distinct receptor chains, which are used 
for signaling by members of the IFN, IL-10 and IL-10-related cytokines, as well as the 
unrelated factor VII (FVIIa) to mediate their biological activities 164,165. 
4.5 IFN receptors 
The three IFN families use distinct receptors to signal, which results in slightly different 
signaling pathways and ultimately variation in their respective biological activities69. The type 
I IFNs signal through the IFNαR1 and IFNαR2 complex 166, while IFNγ binds to a complex of 
IFNγR1 and IFNγR2 167. In contrast the type III IFNs bind to a receptor that utilizes a unique 
IFNλ receptor chain 1 (IFNλR1) in combination with the IL-10R2 chain, which is shared by IL-
10, IL-22 and IL-26 receptor complexes 118,119,127. Several of the receptors can be alternatively 
spliced which leads to both membrane-bound or secreted soluble forms 164. The soluble 
receptor forms are usually identical in the extracellular domain but lack the transmembrane 
and intracellular domains 168, and are known to participate in signaling and its regulation 169. 
For example, mice have an alternative soluble form of IFNαR2 that seems to be 
independently regulated from the membrane bound form 170,171. These soluble forms have 
been thought to act as decoys, whereby they inhibit the binding of the ligand to the 
membrane bound form 168. Thus the soluble form of IFNλR1 was found to antagonize IFNλ 
activity 172. However, in vitro studies on IFNαR2 have suggested that the soluble receptor can 
interact with IFNα and the membrane bound IFNαR1 to promote signaling 171. Therefore, 
while soluble receptors are clearly important in controlling cytokine signaling pathways and 
immune responses, their exact role is not yet well understood.  
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4.6 IFNλ receptor complex 
Type III IFNs act through a unique transmembrane receptor complex which consists of the 
IFNλR1 and the IL-10R2 chains 118,119 (Figure 4-6).When either of these chains is absent or 
neutralized by an antibody, cells are unresponsive to IFNλ 119,159, showing that both IFNλR1 
and IL-10R2 are needed to form a functional receptor 166. The crystal structure of IFNλR1 
indicates that it is most similar in structure to IL-10R1 and IL-22 binding proteins 121, which is 
perhaps not surprising since all interact with IL-10R2. Studies investigating the potential 
competitive inhibition of other IL-10R2 ligands, IL-10 and IL-22, on IFNλ signaling showed 
that while the presence of IL-10 was able to suppress the effects of IFNλ by unknown 
mechanisms, no direct competitive inhibition for binding to the IL-10R2 chain was found 
173,174. 
IFNλ signals via a heterodimeric receptor complex consisting of IFNλR1 and IL-10R2. Ligand 
binding brings the associated Janus kinase 1 (JAK1) and Tyrosine kinase 2 (TYK2) proteins 
into close proximity, which leads to cross-phosphorylation and phosphorylation of the 
receptor complex. This facilitates the recruitment of signaling molecules, notably including 
STAT1 and STAT2. These also become phosphorylated allowing them to form a trimeric 
complex with the Interferon Response Factor 9 (IRF9) termed the Interferon Stimulated 
Gene Factor (ISGF3). ISGF3 can translocated to the nucleus interact with Interferon 
Stimulated Response Elements (ISREs) to mediate transcription of ISGs. 
4.6.1 Expression and distribution 
Ultimately the pattern of receptor expression determines which cells respond to a particular 
ligand. Although type III IFNs bind to a unique receptor complex, the downstream signaling is 
similar to that of type I IFNs including gene induction and biological activities 175. However in 
mammals, unlike their type I counterparts, the IFNλR1 is predominantly expressed on 
epithelial cells, like skin, lung, intestine, colon, stomach liver and reproductive tract, as well 
as on specific subsets of immune cells 135,152,159,176-179. It was believed that endothelial and 
fibroblast cell lines do not express IFN λR1 but evidence has emerged that show an effect on 
Figure 4-6 The IFN lambda receptor signaling cascade  
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endothelial cells of the blood brain barrier and in the neuro-invasion of West Nile virus, 
clearly demonstrating that endothelial cells have a response to IFNλ 180. This suggests that 
the type III IFN system has evolved to protect the barriers like the mucosa and the blood 
brain barrier against pathogens 159, in contrast to the type I system, the receptors for which 
are expressed on all nucleated cells 181. Liver, pancreatic and colorectal carcinoma cell lines 
also express IFNλR1 and are therefore susceptible to type III IFN signaling142,159,179. 
4.6.2 IFNλ receptor signal transduction 
The binding of a cytokine to its cognate receptor initiates a signaling cascade which results in 
changes of the physiological state of the cell 56. A variety of signaling cascades have been 
identified that are utilized by cytokine receptors to mediate the cell response 182. One key 
pathway is named the Janus Kinase-Signal transducer and activator of transcription (JAK-
STAT) pathway. The JAK family comprises four members, JAK1, JAK2, JAK3 and Tyrosine 
kinase 2 (TYK2), and the STAT family comprises seven members, STAT1-4 5a,5b and 6 183,184. 
IFNλ initially binds to the IFNλR1 chain, which causes a conformational change that enables 
recruitment of the IL-10R2 to form a trimer. This activates the intracellularly associated 
tyrosine kinases JAK1 and TYK2 to mediate phosphorylation of the receptor chains. This 
creates docking sites for various cytosolic signaling molecules including the latent 
transcription factors STAT1 and STAT2 120. Signaling through type III (and type I) IFN receptor 
complexes results in the formation of a transcription factor complex known as IFN 
stimulated gene factor 3 (ISGF3) 128,146. This complex consists of 3 proteins, STAT1, STAT2, 
and IFN regulatory factor-9 (IRF-9) 120. Once assembled, ISGF3 translocates to the nucleus 
where it binds to IFN stimulated response elements (ISREs) in the promoters of various 
interferon stimulated genes (ISGs) 185. Despite different receptor complexes being employed 
there is a distinct signaling overlap between type I and III IFNs, largely due to convergent 
STAT activation, which helps explain why the antiviral outcomes are so similar 128,146,178,185. 
However, other signaling molecules also contribute to the induction of antiviral genes. For 
example, activation of mitogen-activated protein kinases (MAPK) like ERK, p38 and JNK leads 
to recruitment of auxiliary transcription factors that co-operate with the ISGF3 complex to 
enhance its transcriptional activity 186,187. The type III IFN activates a number of MAP kinases, 
relying to a greater extend on p38 and JNK for gene induction when compared to the type I 
IFNs 146,152.  
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4.7 The chicken IFN system 
4.7.1 Chicken type I IFN 
Chicken IFNs were those first discovered in 1957 by Isaacs and Lindenmann while growing 
influenza virus in chicken chorio-allantoic membrane 60. Originally they were named IFN1 
and IFN2 but Lowenthal and colleagues proposed the standard type I nomenclature be 
applied and therefore they were re-named IFNα and IFNβ, respectively 188.In chickens, IFNα 
consists of a multi-gene family, while only one member of IFNβ has been found. The 
encoded chicken IFNβ shares 58% homology to IFNα but neutralization studies with anti-
IFNα antibodies confirmed that IFNβ was a distinct cytokine 189. All type I IFNs are intron-less 
and located on the Z chromosome, which denotes the male sex chromosome in birds 189,190. 
The chicken type I IFNs were found to be strongly induced in response to infection by a 
number of viruses, such as influenza A virus and Newcastle disease virus (NDV) 191. 
Examination of the promoter regions of chicken type I IFNs has revealed putative binding 
sites for IRFs in all genes, and an NFκB site only in the IFNβ promoter, similar to the situation 
observed in mammals 192. Recombinant chicken IFNα and IFNβ expressed in bacteria or COS 
cells displayed appreciable antiviral activity that was comparable to their mammalian 
counterparts 189. Recombinant forms of chicken IFNα suppressed the growth in vitro of many 
viruses, such as Marek’s disease virus (MDV) 193, infectious bursal disease virus (IBDV) 194 and 
infectious bronchitis virus (IBV) 195. Chicken IFNα was also shown to also inhibit the 
replication of influenza A virus (H9N2) infection in ovo as well as in vivo 196.  
4.7.2 Chicken type II IFN 
Chicken IFNγ has been identified as a single-copy gene on chromosome 1 197. It 
demonstrates high homology to mammalian IFNγ and has been shown to have similar 
biological activities, such as induction of nitric oxide production in macrophages, antiviral 
activities against vesicular stomatitis virus (VSV) in vitro, and up-regulation of MHC class II 
expression 198-200.  
4.7.3 Chicken type III IFN 
Computational techniques enabled the identification of a single chicken IFNλ gene on 
chromosome 7 65,201. The genomic structures of both mammalian and chicken IFNλ genes are 
similarly organized into 5 exonic regions 118,119,201. The encoded chicken IFNλ has a higher 
amino acid identity to human IFNλ2 compared to IFNλ1 and IFNλ3, and an even lower 
identity to the chicken type I or type II IFNs 201. Chicken IFNλ has been recombinantly 
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expressed and its biological function investigated in a number of assays. Chicken IFNλ 
displayed inhibitory activity against Semliki Forest virus (SFV) and influenza A virus, in a 
similar manner to that observed for the type I chicken IFN. However, the overall activity of 
chicken IFNλ was lower than its type I chicken IFN counterparts, consistent with findings in 
human and mouse models 201.  
4.7.4 Chicken IFN receptors 
Only a few chicken CRF2 genes have been cloned or characterized to date. The IFNαR1, 
IFNαR2, IFNγR2 and IL-10R2 genes were found to cluster on chicken chromosome 1 in a 
similar fashion to that seen in the human 202, with IFNγR1 203 also identified. Previous studies 
have also indicated the presence and activity of the JAK-STAT pathway components in birds 
204,205, which would suggest conserved downstream signaling, although functional 
confirmation remains lacking. IFNλR1 mRNA expression has been described in chicken heart, 
liver, kidney, intestine, lung and trachea 206.  
4.8 Interferon stimulated genes 
The antiviral activity of IFNs is mediated by hundreds of genes upregulated upon IFN 
stimulation called ISGs 207. These genes encode proteins that are able to interfere with the 
virus life cycle at different stages and so play a key role in IFN mediated antiviral defence. 
The antiviral effector ISGs can be grouped into three main categories 207: (i) proteins that act 
as inhibitors of viral entry like the Myxovirus resistance gene 1 (Mx1) 208; (ii) proteins that 
interfere with viral replication like the zinc finger antiviral protein (ZAP) 209, the IFN-induced 
double-stranded RNA dependent protein kinase (PKR) 210 or the interferon inducible protein 
with tetratricopeptide repeats (IFIT) gene family 211; and, lastly (iii) proteins that inhibit viral 
budding, like the virus inhibitory protein, endoplasmic reticulum (ER) associated, interferon 
inducible (Viperin) 212. 
4.8.1 Mx1 
The mouse Mx1 gene belongs to the dynamin GTPase family 213 and was one of the first 
genes described to affect viral entry. Its encoded protein is specifically involved in blocking 
viral entry into the nucleus 214 via association with vesicular COP I, leading to sequestering of 
essential viral compartments within the cell 215. The chicken Mx1 gene has been studied 
extensively for its role in influenza virus infections 216. Some publications claim that chicken 
Mx1 is antiviral 217 while others show no antiviral benefit 216,218,219. The chicken Mx1 gene is 
very polymorphic 218 with several different haplotypes identified across chicken breeds 220, 
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although potential differences between these haplotypes in antiviral protection has yet to 
be determined.  
4.8.2 ZAP 
ZAP is an accessory factor that recognizes viral RNA and promotes viral RNA degradation via 
the RNA exosome 221 thereby inhibiting translation of incoming viral RNA 222. The chicken 
homologue of ZAP has previously been identified and characterized 223. 
4.8.3 PKR 
PKR is a RNA-dependent protein kinase that upon recognition of dsRNA phosphorylates the 
eukaryotic initiation factor-2α, which then blocks viral protein synthesis by disrupting 
delivery of tRNAs to the 40S ribosomal subunit 224. PKR has also been shown to be involved 
in the activation of signal transduction pathways leading to IFNβ gene expression 225. The 
chicken PKR gene has been identified and characterized 226.  
4.8.4 IFIT 
The various IFIT family members, IFIT1-5, have been shown to play critical roles in antiviral 
defence in humans and mice 211. The mechanisms are not completely understood but IFIT1 
and IFIT2 have been shown to suppress translation by binding to the eukaryotic initiation 
factor 3 211. Furthermore, IFIT family members can also directly bind to single-stranded RNA 
211,227 and double-stranded DNA 228 and thereby reduce viral replication. The chicken IFIT has 
been mentioned in several publications229 230,231 but a comprehensive characterization of the 
gene has not been performed. 
4.8.5 Viperin 
Viperin has been shown to interfere with the viral life cycle of many viruses by as yet 
unknown mechanisms 212. Some groups have suggested that viperin inhibited replication of 
certain viruses 232,233, while others have shown that it disturbs lipid rafts to restrict budding 
of influenza A viruses 234 and HIV 235. Chicken viperin has been identified and characterized 
236. 
4.9 Rationale 
Highly pathogenic avian influenza (HPAI) infections such as H5N1 and H7N9 cause significant 
morbidity and mortality in chickens worldwide 237. This has widespread consequences, 
including devastating effects on the poultry industry 238 leading to severe economic losses 239 
and bottlenecks in meat supply, since the method of choice to limit the spread of the virus is 
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the mass culling of infected chicken flocks 240. There is also the potential for zoonotic 
transmission to humans 237,241-243, with most human infections of HPAI associated with direct 
transmission from avian hosts with little or no evidence of human-to-human transmission 
244,245. Therefore, the ability to stop HPAI infection in chicken would be a very attractive. 
Knowledge in the field of mammalian antiviral defence is advanced, with studies in mice 
playing a crucial role in the advancement of knowledge regarding antiviral immunology and 
host pathogen interaction 246. In contrast information on the avian immune response 
currently remains limited. Moreover, there are distinct differences in mouse physiology and 
immunology compared to natural pathogen reservoir species as well as spill over hosts 246,247. 
This clearly indicates the need for more studies in avian species to better understand 
pathogenicity of viruses such as HPAI to underpin the development of means to prevent the 
spread of these pathogens 248.  
4.9.1 Hypothesis 
The studies in this thesis seek to investigate the hypothesis that the IFNλ signalling complex 
is involved in the antiviral immune response in chickens. 
4.9.2 Aims 
The research addresses following specific aims: 
x To characterize the expression of chicken IFNλ and its effect on in vitro and in vivo 
ISG expression in comparison to IFNα. 
x To identify and confirm the chicken IFNλR complex and downstream signaling 
effector molecules. 
x To identify and characterize the chicken IFIT5 gene. 
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5 Material and Methods 
5.1 Cell culture  
5.1.1 Chicken splenocytes 
Chicken splenocytes were purified as described previously 201. Briefly, spleens from 4-6 week 
old (unless otherwise specified), specific-pathogen free (SPF) chickens were harvested and 
dispersed through a 70 μm mesh sieve (BD Falcon). The mononuclear cells were then 
purified using density gradient centrifugation (Lymphoprep – Nicomed Pharma). After 
washing, the cells were counted and 4x106 cells per well transferred to 24 well plates (Nunc) 
and cultured in DMEM high glucose media (Life Technologies) containing 10% (v/v) fetal calf 
serum and 1000 U/mL penicillin and streptomycin (Sigma).  
5.1.2 DF1 cells  
DF1 cells were maintained in DMEM high glucose media (Life Technologies) containing 10% 
(v/v) fetal calf serum and 1000 U/mL penicillin and streptomycin (Sigma) at 37°C with 5% 
CO2. After passaging the cells were counted and 6x104 cells transferred into a 24 well plates 
(Nunc) and kept at 37°C with 5% CO2 overnight.  
5.1.3 Transfection 
Cells were washed and cultured in 400 μl Optimem per well. Per well 2 μl Lipofectamine 
2000 (Invitrogen) and 4 nM siRNA were incubated at RT for 30 min then 10% DMSO (v/v) 
was added and the mix transferred onto the cells. These were incubated at 37°C with 5% CO2 
for 12 h before the media was changed back to full growth media for 48 h. 
5.1.4 Cell stimulation 
After passaging the cells were counted and 6x104 cells were transferred into a 24 well plates 
(Nunc) and kept at 37°C with 5% CO2 overnight. 
Cells were stimulated with 50 μg/mL of poly (I:C) (Invitrogen), 10 μg/mL lipopolysaccharide 
(LPS) purified from E. coli strain 0111:B4 (gamma irradiated, 500000 EU/mg) (Sigma Aldrich), 
500 ng/mL recombinant chicken IFNα (Genway Biotech) or 50 μg/mL recombinant chicken 
IFNλ, kindly provided by Dr Tim Adams (CSIRO Manufacturing). The chIFNα was produced in 
an E. coli expression system while the chIFNλ was produced within an mammalian system 
utilizing CHO cells both were tested for the absence of endotoxins. In some experiments 
cells were pre-treated with 1 nM Ruxolitinib (Selleck Chemicals) per well for 2 h. The doses 
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for each compound were initially taken from literature or MSDS and confirmed by in vitro 
experiments on chicken primary or cell lines to be the most effective dose for (data not 
shown). 
5.2 In vivo studies 
5.2.1 Ethics 
All animal work was conducted with the approval of the CSIRO Australian Animal Health 
Laboratory Animal Ethics Committee (permit number 1610). All procedures were conducted 
according to the guidelines of the National Health and Medical Research Council as 
described in the Australian code for the Care and Use of Animals for Scientific Purposes. All 
birds were obtained from  Australian SPF Services P/L (Woodend, Australia). 
 
5.2.2 Egg trial (H1N1) 
D10 embryonated chicken eggs were inoculated with 100 μl of 1:10000 diluted virus stock 
A/Puerto Rico/8/1934 H1N1 of 6.4 x 10^8 pfu/mL (kindly provided by Dr. Siying Ye and Dr. 
John Stambas), incubated at 37°C for 24 or 48 h and then chilled at -20°C for 20 min and post 
mortems performed. The tissues were placed into 2 mL tubes (Sarstaed) with Graphite 
beads (Daintree Scientific) and RLT buffer (Qiagen) and homogenized twice for 20 s each. 
Tissue homogenate was then stored at -80°C for RNA extraction. 
5.2.3 Virus propagation 
A highly pathogenic avian influenza virus A/duck/Laos/XBY004/2014 (H5N6) (Lao/14), 
isolated from pooled duck tissues from Lao PDR 31, was used in this study. Virus was 
propagated according to accepted protocols 249, briefly: After wiping with 70% (v/v) ethanol 
a small incision was punched into the egg shell  the virus was introduced by allantoic cavity 
inoculation of D9–11 embryonated SPF chicken eggs. The incision was then sealed with 
wood glue and the eggs incubated at 37°C for 48 h The virus stock was titrated in chicken 
eggs and the 50% egg infectious dose (EID50)/mL was calculated according to the method of 
250. 
5.2.4 Animal trial (H5N6) 
Six 5-week-old SPF chickens were used for experimental infections. Samples from six 
uninfected chickens from the same cohort were used as controls. Prior to challenge, serum 
was collected from each chicken to confirm that birds were serologically negative for avian 
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influenza A virus, as determined by blocking ELISA 251. Each chicken was inoculated with a 
dose of 106 EID50 of Lao/14 in 0.2 mL by the oral-nasal-ocular route. Chickens were observed 
closely from 22 hpi and were euthanized at a humane endpoint defined as progression to 
moderate signs of disease, including facial swelling, diarrhoea, hunched posture with ruffled 
feathers, drooping wings, huddling, recumbency, depression and slow response to 
stimulation. In accordance with Institutional Animal Welfare Policies, chickens were 
euthanized by cervical dislocation following heart bleed under anesthesia (44 mg/kg 
ketamine, and 8 mg/kg xylazine injected intramuscularly). Immediately after euthanasia, 
swabs (oral and cloacal) were taken and approximately 100 mg of tissue from the spleen and 
lung were collected into sterile 2 mL tubes containing PBS with antibiotics and a small 
quantity of 1 mm silicon carbide beads (BioSpec Products). Tissue samples were 
homogenized twice for 20 s in a FastPrep24 tissue homogenizer (MP Biomedicals) for 
bioassays. The presence of influenza viral genome within swabs, tissues samples was 
assessed by extracting total RNA from each sample (MagMax-96 Total RNA Isolation Kit, Life 
Technologies) for testing using a pan-influenza A matrix gene real-time RT-PCR assay 252. 
Cycle threshold (Ct) values for each sample were compared to those obtained for a set of 
RNA transcripts encoding the Lao/14 matrix genome segment to convert each sample Ct 
value into a value representing the number of copies of the matrix genome segment per μl 
of sample. These RNA transcripts were generated using T7 RNA polymerase (Promega) and a 
plasmid encoding the Lao/14 matrix genome segment cloned into the pGEM-T-Easy cloning 
vector (Promega). The complete data set can be found in Butler et al 2016 253 
5.3 Bioinformatics 
5.3.1 Primer design and domain prediction 
Protein sequences were retrieved from the Ensembl genome database (www.ensembl.org) 
except for KF956064, which was retrieved from Genbank (www.ncbi.nlm.nih.gov/genbank). 
Primer design, sequence assembly and initial alignment was performed using CLC-Main 
Workbench 7.6.3.  
5.3.2 Phylogenetic analysis 
All Sequences were retrieved from Genbank (www.ncbi.nlm.nih.gov/genbank). Protein 
alignments used the MUSCLE algorithm and phylogenetic trees were calculated using MEGA 
6.0. Accession Numbers of all sequences used in this analysis are given in the Appendix. 
Table 2 (IFNs) 
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Table 3 (IFNλR) 
Table 4 (IFNAR1) 
Table 5 (IL10R2) 
Table 6 (IFITs) 
5.4  Molecular methods 
5.4.1 RNA isolation and reverse transcription 
Total RNA was harvested from cultured cells using the Qiagen RNAeasy extraction kit 
according to the manufacturer’s instruction, and from tissues using TRIzol (Life 
Technologies). Prior to qRT-PCR for gene expression analysis, RNA samples were 
subsequently treated with RNAse-free DNase (Promega) and reverse transcribed with a 
Superscript III cDNA synthesis kit (Life Technologies). 
 
5.4.2 Cloning and sequencing  
The chIFIT5 gene was amplified using Platinum Taq Master mix (Life Technologies) with gene 
specific primers (forward primer: 5’-ATGAGTACCATTTCCAAGAAT, reverse primer: 5’-
TAGCTTGAGAGGGAAAG) and cloned into the pGEM-T-Easy vector (Promega) using T7 Ligase 
(Promega) and transformed into Escherichia coli DH5α (Life Technologies), according to 
manufacturer’s instructions. Plasmids were purified using a Qiagen Plasmid Miniprep kit and 
sequencing was performed by the Micromon Sequencing Facility (Monash University). 
5.4.3  Quantitative Real Time PCR (RT-PCR) 
Gene expression was quantified in DF1s, splenocytes and lung and spleen tissues by RT-PCR 
using TaqMan Universal PCR master mix (Life Technologies) with FAM reporter dye and NFQ 
quencher and primer probe pairs obtained from Applied Biosystems (Table 7). Temperature 
profile for the RT PCRs was: 50oC 2 min, 95oC 10 min, 40 cycles of 95oC 15 sec and 60oC 1 
min. 
 
5.4.4  Electrophoretic mobility shift assay (EMSA). 
Nuclear extracts were prepared as described previously 254. Briefly, cells were stimulated , 
pelleted and resuspended in ice-cold hypotonic buffer (2 mM HEPES pH 7.8 (Sigma), 20 mM 
NaF (Sigma), 1 mM Na3VO4 (Sigma), 1 mM DTT (Sigma), 1 mM EDTA (Sigma), 50 μg/mL 
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Protease inhibitors (Sigma), 1 mM Tween-20). Cells were then briefy and the nuclei pelleted 
by centrifugation at 15,000g for 30 s. Nuclear extracts were prepared by resuspension of the 
nuclei in high-salt buffer (hypotonic buffer with 420 mM NaCl (Sigma) and 20 % (v/v) 
glycerol) and extraction of proteins by rocking for 30 min at 4°C. Insoluble materials were 
removed by centrifugation at 4°C for 15 min at 15,000g and nuclear extracts were stored at -
80°C for analysis. 
Nuclear extracts were incubated for 20 minutes at room temperature with 32P-labeled 
double-stranded m67 oligonucleotide (5’-CATTTCCCGTAAATC), a high-affinity mutant of the 
sis-inducible element (SIE) and poly(dI-dC) in binding buffer (13 mmol/L HEPES, pH 7.8, 80 
mmol/L NaCl, 3 mmol/L NaF, 3 mmol/L NaMoO4, 1 mmol/L DTT, 0.15 mmol/L EDTA, 0.15 
mmol/L EGTA, and 8% glycerol). The DNA-protein complexes were separated by 
electrophoresis on 5% polyacrylamide gels containing 5% glycerol in 0.25 x Tris-buffered 
EDTA (TBE). The gels were dried and subsequently exposed to phosphoimager screens and 
analyzed with ImageQuant software (Molecular Dynamics). 
  
34 
 
6 Characterization of chicken IFNλ signaling 
6.1 Introduction 
The interferons (IFNs) were discovered by Isaacs and Lindenmann in the chorio-allantoic 
membrane of chicken eggs with the isolated protein first described as “a substance that was 
able to interfere with the virus’ ability to infect cells”60. Since then the knowledge about IFNs 
has increased dramatically, although most these studies have been performed in mammals. 
IFNs are expressed by virtually all cells of the body upon sensing of viral PAMPs via PRRs 
such as TLRs 38,44. Of the thirteen TLRs identified six are considered to function as antiviral 
sensors either through the detection of viral glycoproteins on the cell surface (via TLR2 and 
4) or through recognition of dsRNA in the endosome (via TLRs 3,7, 8 and 9) 45-51. In addition 
to the TLRs, intracellular sensors such as RIG-I and MDA-5 are involved in the cytosolic 
recognition of foreign nucleic acids 52 although in chickens MDA-5 appears to have taken 
over some of the roles of RIG-I that it is absent in this species 255. 
Three IFN families have been identified which are called type I, type II and type III. IFNs are 
assigned to these families according to their receptor specificity and signaling pathways, 
which defines downstream gene induction although overlaps occur in these features 
between families 64-66. Type I IFNs consist of at least 8 subclasses with the IFNαs and IFNβ as 
their most prominent members 1,22, type II consists of IFNγ and type III comprises IFNλs of 
which there are four in humans but only one in the chicken 201. All types of IFN contribute to 
the antiviral immune response but only type I and III have a direct antiviral effect 59, which is 
mediated by a group of hundreds of antiviral genes called ISGs 207. 
Similarities between type I and type III IFNs have been described concerning gene induction 
and antiviral properties 146,175. However, each of these families signal through a unique 
receptor complex consisting of two chains; for type I IFNs these are IFNAR1 and IFNAR2256 
and for type III IFNs these are IFNλR1 and IL-10R2 118,119. Recent studies have identified 
unique roles for IFNλs in antiviral defense, and there is emerging evidence that IFNλs may 
have functional importance beyond innate antiviral protection 128.  
This Chapter focuses on advancing our understanding of the biological activities of chicken 
type III IFN particularly the similarities and differences with respect to type I IFN. 
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6.2 Results 
6.2.1 Phylogenetic analysis of the chicken type I/III IFNs  
To obtain an initial insight into the relative homology between the chicken and mammalian 
IFN systems phylogenetic analysis of type I and type III IFNs from chicken, human and mouse 
was performed (Figure 6-1). Unsurprisingly, the IFNαs of both human and mouse clustered 
together in separate groups, which collectively were distinct from other human and mouse 
type I IFNs like IFNο, IFNζ and IFNκ. Chicken type I IFNs, IFNα and IFNβ, clustered together in 
a subgroup linked with human and mouse IFNβ and IFNε. The chicken IFNλ grouped with the 
mammalian IFNλ proteins that clustered by species. This suggested overall conservation, 
including distinct type I and type III members between chickens and mammals. 
6.2.2 Dose response of chicken IFNs to poly (I:C) 
Poly (I:C) (PIC) is a powerful inducer of IFNs 257. It serves as a mimic of viral RNA and so is 
able to trigger PRRs like the TLR family and MDA-5. To examine induction of IFNα and IFNλ 
by PIC purified chicken splenocytes were cultured in vitro with different concentrations of 
PIC for 3 h and IFN mRNA levels analyzed by qRT-PCR (Figure 6-2). Both IFNs were induced 
even by low concentrations of PIC. Indeed, IFNα reached its peak expression with a 5-fold 
upregulation at 1 μg/mL that was similar up to 100 μg/mL. In contrast IFNλ expression 
increased up to 10 μg/mL where it maintained a peak level of expression at around 600-fold 
upregulation compared to the untreated control. 
6.2.3 Time course of TLR-dependent stimulation of chicken IFNs 
To further investigate the type I versus type III IFN response, the timing of TLR-mediated IFN 
induction was analyzed following stimulation with PIC as well as lipopolysaccharide (LPS), 
another TLR agonist 258. Chicken splenocytes were treated with either PIC (Figure 6-3A) or 
LPS (Figure 6-3B) and IFN expression measured at different time points. PIC treatment led to 
a rapid and robust upregulation of both IFNs, being increased after 0.5 h and peaking at 30-
fold for IFNα and 100-fold for IFNλ at 1.5-3 h, followed by a decline to close to base-line 
expression by 24 h post stimulation. LPS treatment, in contrast, failed to induce any 
significant upregulation of either IFNα or IFNλ at any time points measured.  
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Figure 6-1 Phylogenetic analysis of the type I/III IFNs 
The evolutionary history of the type I and type III IFNs from human, mouse and chicken was 
inferred by using the Maximum Likelihood method based on the JTT matrix-based model 259. 
The tree with the highest log likelihood (-10509.0810) is shown. The accession numbers of all 
sequences used can be found in the Appendix (Table 1). 
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Figure 6-2 Dose response of chicken IFNs to poly (I:C) 
Expression of IFNα and IFNλ mRNA in purified chicken splenocytes from SPF chickens 
stimulated with poly (I:C) at the concentrations indicated. The bars represent the mean fold 
change of 3 chicken spleens with the standard error of the mean (SEM) compared to the 
untreated sample, normalized against the housekeeping gene GAPDH (* p value < 0.05 using 
a one-way ANOVA test with Fischer’s uncorrected LSD test). 
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Figure 6-3 Time course of TLR-dependent stimulation of chicken IFNs 
Expression of IFNα and IFNλ mRNA in purified splenocytes from SPF chickens stimulated with 
50 μg/mL PIC (A) and 10 μg/mL LPS (B) over the indicated times. The bars represent the 
mean fold change of 3 chicken spleens with the standard error of the mean (SEM) compared 
to the untreated sample, normalized against the housekeeping gene GAPDH (* p value < 
0.05, *** p value < 0.001 using a one-way ANOVA test with Fischer’s uncorrected LSD test). 
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6.2.4 Time course of IFN mediated induction of chicken IFN expression 
Self-induction and/or positive feedback loops for IFNs exist in mammals, where they play an 
important role in signal amplification 260. Since this has not previously been investigated in 
birds, splenocytes from SPF chickens were exposed to recombinant chicken IFNα Figure 
6-4A) and recombinant chicken IFNλ (Figure 6-4B) and levels of IFN mRNAs quantified. IFNα 
stimulation did not significantly induce IFNα or IFNλ mRNA expression across all chickens at 
any time points measured although induction was observed in a subset (two) of chickens. 
IFNλ treatment in contrast upregulated IFNλ slightly up until 6 h but by 48 h a 3000-fold 
increase was observed. IFNλ stimulation caused IFNα mRNA levels to decrease until 24 h, but 
with a later upregulation to 350-fold at 48 h. 
6.2.5 Characterization of TLR-dependent ISG responses  
TLR responses in chicken cells have been previously described 261, but the timing of ISG 
induction has not been well characterized. Splenocytes from SPF chickens were stimulated 
with PIC (Figure 6-5A) and LPS (Figure 6-5B) and ISG expression quantified. The PIC 
treatment led to a sharp increase in ISG expression at 3 h, with a peak expression level for all 
ISGs at 6 h post stimulation, followed by a decline to base-line levels after 48 h. Mx1 showed 
the highest induction of approximately 170-fold followed by Viperin at around 70-fold, with 
induction of Zap and PKR peaking at around 10-fold at the 6 h time point. LPS stimulation 
gave a similar kinetics of ISG induction, with peak expression at 6 h and then a decline to 
base-line expression around 48 h. The magnitude of induction was similar for Viperin 
(approximately 50-fold) as well as PKR and ZAP (around 12-15-fold), but Mx1 induction was 
substantially reduced (around 20-fold).  
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Figure 6-4 Time course of IFN-mediated induction of chicken IFN expression 
Expression of IFNα and IFNλ mRNA in purified splenocytes from SPF chickens stimulated with 
500 ng/mL IFNα (A) and 50 μg/mL IFNλ (B) over the indicated time course. The bars 
represent the mean fold change of 3 chicken spleens with the standard error of the mean 
(SEM) compared to the untreated sample, normalized against the housekeeping gene 
GAPDH (*** p value < 0.001 using a one-way ANOVA test with Fischer’s uncorrected LSD 
test).  
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Figure 6-5 Characterization of TLR-dependent ISG response 
Expression of Mx1, PKR, Viperin and Zap mRNA in purified splenocytes from SPF chickens 
stimulated with 50 μg/mL PIC (A) and 10 μg/mL LPS (B) over the indicated time course. The 
bars represent the mean fold change of 3 chicken spleens with the standard error of the 
mean (SEM) compared to the untreated sample, normalized against the housekeeping gene 
GAPDH (* p value < 0.05, *** p value < 0.001 using a one-way ANOVA test with Fischer’s 
uncorrected LSD test). 
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6.2.6 Characterization of the type I/III IFN-mediated ISG response  
In mammalian systems profound differences between type I and type III interferons have 
been described, both in the magnitude of the ISG response as well as its timing 157. To better 
understand the IFN response in chickens, the time-dependent expression of several well 
characterized ISGs was evaluated. Splenocytes from SPF chickens were treated with chIFNα 
(Figure 6-6A) or chIFNλ (Figure 6-6B). ChIFNα treatment led to a rapid increase of all ISGs 
investigated with similar kinetics, a sharp rise in expression levels after 3 h with a peak at 
around 6 h and then a decline to 48 h. Although having similar induction kinetics, the 
magnitude of the responses differed between the genes, with Mx1 and Viperin showing 
highest upregulation at around 40 and 30-fold increase, respectively, while both PKR and 
ZAP expression levels showed an approximately 8-fold increase during the peak at 3 h post 
stimulation. In contrast, chIFNλ stimulation of these cells led to a considerably delayed 
induction of ISGs. A small increase was apparent by 1.5 to 3 h, with peak induction at 48 h 
post stimulation. By this time, both Viperin and Mx1 were highly induced, with a 20-fold and 
10-fold increase at the 48 h time point, respectively. No significant increase in ZAP or PKR 
expression was observed following chIFNλ stimulation. 
6.2.7 Characterization of the IFN response following acute HPAI H5N6 infection  
To evaluate the involvement of type I and III IFNs in vivo, RNA was extracted from spleens 
and lungs of H5N6 infected and uninfected chickens at 24 h post infection and the levels of 
IFNα and IFNλ measured by qRT-PCR. In the spleen of infected chickens (Figure 6-7A) IFNα 
was induced 9-fold and IFNλ almost 70-fold compared to uninfected animals. In the lungs 
(Figure 6-7B), the primary site of infection, both IFNs were highly induced, with a 25-fold 
increase of IFNα and a 60-fold increase in IFNλ compared to uninfected birds.  
6.2.8 Characterization of ISGs expression following acute HPAI H5N6 infection 
ISGs are key mediators of the antiviral immune response mediated by IFNs. Therefore, the 
expression of some of the most important antiviral genes was examined during acute HPAI 
infection. In the spleen of infected chickens Mx1 gene expression was induced 230-fold 
compared to uninfected controls with PKR being slightly lower at around 40-fold, but no 
significant upregulation of ZAP expression was observed (Figure 6-8A). In the lungs, 
expression of Mx1 was induced 65-fold and PKR around 60-fold with ZAP again not 
upregulated (Figure 6-8B). 
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Figure 6-6 Characterization of the type I/III IFN-mediated ISG response  
Expression of Mx1, PKR, Viperin and Zap mRNA in purified splenocytes from SPF chickens 
stimulated with 500 ng/mL IFNα (A) and 50 μg/mL IFNλ (B) over the indicated time course. 
The bars represent the mean fold change of 3 chicken spleens with the standard error of the 
mean (SEM) compared to the untreated sample, normalized against the housekeeping gene 
GAPDH (* p value < 0.05, **** p value of <0.0001 using a one-way ANOVA test with Fischer’s 
uncorrected LSD test).  
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Figure 6-7 Characterization of IFN response following acute HPAI H5N6 infection  
Expression of IFNα and IFNλ mRNA in the spleen (A) and lung (B) of six 5-week old SPF 
chickens 24 hours post infection with Influenza virus A/duck/Laos/XBY004/2014 (H5N6). 
Data is shown as the mean fold change of mRNA expression with the SEM compared to the 
same tissue of the uninfected birds, normalized against the housekeeping gene GAPDH (* p 
value < 0.05 using the Students t test with Mann Whitney U test). 
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Figure 6-8 Characterization of ISG response following acute HPAI H5N6 infection 
Expression of Mx1, Pkr and Zap mRNA in the spleen (A) and lung (B) of six 5-week old SPF 
chickens 24 hours post infection with Influenza virus A/duck/Laos/XBY004/2014 (H5N6). 
Data is shown as the mean fold change of mRNA expression with the SEM compared to the 
same tissue of the uninfected birds, normalized against the housekeeping gene GAPDH (* p 
value < 0.05 using the Students t test with Mann Whitney U test). 
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6.2.9 Comparison of type I and III IFN expression between male and female 
chickens. 
Recent evidence from mice and humans suggests that females and males differ in the 
magnitude of immune responses particularly with regards to IFNs, with a link to female 
hormone levels also suggested 262,263. To examine this possibility in chickens, splenocytes 
from immature female and male chickens were treated with PIC (Figure 6-9A/B/C) with 
blood estradiol levels of each bird measured in parallel (Figure 6-9D). IFNα mRNA levels 
(Figure 6-9A) were relatively tightly grouped: males tended to have higher levels earlier but 
females tended to show a significantly higher peak at 2 h. The IFNβ mRNA levels (Figure 
6-9B) followed the same trend as IFNα, with significantly higher female expression at 2 h. 
Interestingly the opposite trend was observed for IFNλ (Figure 6-9C) with males having a 
generally higher expression albeit only reaching significance at the 2 h time point. The 
inability to reach significance at other time points was in part due to highly variable IFNλ 
expression in females compared to the males with several individuals showing negligible 
IFNλ induction. The concentration of serum estradiol was measured in both groups and 
indicated that the immature female chickens had higher levels, ranging from 70-90 pg/mL 
while all the male samples clustered around 60 pg/mL. The experiment was repeated with 
chicken splenocytes from sexually mature male and female chickens. PIC stimulation (Figure 
6-10A) lead to higher mean IFN expression in females which reached statistical significance 
for IFNλ. The estradiol levels (Figure 6-10B) were significantly higher in females ranging from 
300 -1400 pg/mL, with in males again around 60 pg/mL. Single bird correlation of estradiol 
levels and IFN mRNA expression showed no conclusive pattern in female or male birds 
(Figure 6-10C/D).  
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Figure 6-9 Comparison of type I and III expression in immature male and female chickens. 
Expression of IFNα (A), IFNβ (B), IFNλ (C) mRNA in purified chicken splenocytes from 6 
female (circles) and 6 male (triangles) 5-week old SPF chickens stimulated with 50 μg/mL PIC 
over the time course indicated. Symbols represent fold upregulation of each stimulated 
splenocytes sample compared to the untreated sample, normalized against the 
housekeeping gene GAPDH. (For A-C: * p value < 0.05, ** p value < 0.005, *** p value < 
0.001 using a two-way ANOVA with Bonferroni's multiple comparisons test) (D) Blood 
estradiol levels chickens at the time of sacrifice (*** p value < 0.001 using the Students t test 
with Mann Whitney U test).  
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Figure 6-10 Comparison of type I and III IFN expression in mature male and female 
chickens. 
Expression of IFNα and IFNλ mRNA in purified chicken splenocytes from 6 female (circles) 
and 5 male (triangles) 12-week old SPF chickens stimulated with 50 μg/mL PIC for 2 h. 
Symbols represent fold upregulation of each stimulated splenocytes sample compared to 
the untreated sample, normalized against the housekeeping gene GAPDH (A). (B) Blood 
estradiol levels of the chickens at the time of sacrifice. (For A: * p value < 0.05 using a two-
way ANOVA with Bonferroni's multiple comparisons test, for B ** p value < 0.005 using the 
Students t test with Mann Whitney U test). Depiction of IFNα and IFNλ mRNA levels for 
females (C) and males (D) (R2 values indicate the curve fit for a linear regression). 
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6.3 Discussion 
Like other bird species, chickens have a single IFNλ, compared to four members in humans 
125 and two in mice 124. This Chapter sought to further the knowledge base about chicken 
IFNλ, particularly in comparison to type I IFNs. 
Phylogenetic comparison of chicken type I and III IFNs with those of mice and humans 
provided insights into their evolution. IFNαs have separately expanded in both humans and 
mice, forming distinct sub-clades that group together. These formed a larger clade with 
other type I IFNs, including the single IFNβ and numerous alternate IFNs. It has been argued 
that this reflects the strong evolutionary pressure on IFN evolution that is thought to be 
unequal between IFNs 264. Notably, chicken IFNα and IFNβ clustered together, confirming 
their presumed divergence from a common precursor, but also suggesting that species-
dependent evolutionary pressure has driven them to remain relatively highly conserved 
compared to those of other species 68. The IFNγ proteins formed a distinct cluster, indicative 
of a conserved role across species 265, with the human and mouse IFNλs again forming 
separate sub-clades. 
Since their discovery, type III IFNs have been compared to their type I counterparts 118,119. 
Under certain experimental situations, type III IFNs showed similar gene induction to type I 
IFNs but elicited a reduced magnitude of antiviral effect 266,267. This has led to the assumption 
that IFNλs are just a ‘weaker’ form of type I IFNs. However, other studies have found 
significant differences between type I and type III IFNs, including the identification of novel 
roles for the latter 268-270. Whether such differences were present in chickens remained an 
unanswered question. Therefore, the induction and effects of IFNλ were directly compared 
to IFNα in primary chicken splenocytes. Treatment with well-characterized TLR agonists 
revealed differences in dose-response, magnitude and timing of IFN induction. It is worth to 
mention here that all stimulations were executed at 37°C and not the usual temperature for 
avian cells (42°C) due to limitations of incubation space, which may influence the magnitude 
of the response to stimuli. PIC is a viral RNA mimic that triggers TLR3 and initiates a strong 
antiviral response in most cells 47. This was shown to induce IFNα by 3 to 8-fold, whereas 
IFNλ induction was 30-500-fold. Moreover, peak IFNα induction occurred at a lower dose of 
PIC (0.5 μg/mL) compared to IFNλ (10 μg/mL). In contrast the timing of PIC-mediated 
induction of IFNα and IFNλ was similar, with a peak at 1.5-3 h, followed by a decline. These 
results suggest that the two IFNs may have different biological roles, with moderate IFNα 
induction triggered by even low levels of pathogen, whereas a stronger IFNλ induction 
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requires higher pathogen levels. This data is consistent with human and mice experiments 
257,271, suggesting that the pattern of IFN induction is conserved. LPS treatment did not 
upregulate IFNα or IFNλ at any time point, which is in line with observation that infection 
with gram positive bacteria strongly induce IFNλ in lung epithelia and placenta cells but not 
gram negative bacteria 272. Further, studies in human immune cells have shown that only 
IFNλ1 can be upregulated by LPS stimulation while IFNλ2 and λ3 remain unresponsive in 273. 
This suggests that IFNλ1 may have acquired this feature, which is not a general property of 
type III IFNs. It is worth noting that large variations in IFNλ induction were observed between 
birds that limited finer analysis, this may be due to genetic factors as is the case for IFNγ in 
humans 274. In addition, the reduced fold induction of IFNα is likely due, at least in part, to 
the higher basal levels of this IFN.  
Amplification of antiviral signals plays an important role in immune defence, not only 
ensuring that the signal reaches sufficient strength to exert an effective response, but also 
that it is spread to neighbouring cells. These positive feedback loops have been described 
extensively for mammalian IFNs 128,260,275.To investigate whether this mechanism was 
conserved in chickens, purified splenocytes were treated with recombinant IFNα or IFNλ. 
IFNα treatment showed a trend for rapid IFNα upregulation, which then slowly declined. 
Although the results lacked statistical significance due to considerable bird-to-bird variation 
the suggested time frame of self-induction was in agreement with mammalian studies 275,276. 
IFNλ, in contrast, showed no induction by IFNα at any time point, which is different to 
studies in mice where IFNα induced a strong IFNλ induction 135. However, this could be due 
to cell-type specific effects, since IFNλ expression is known to vary between cell types 137,273. 
IFNλ stimulation resulted in a trend for differential regulation of IFNα and IFNλ early, but by 
48 h led to a significant upregulation of both IFNα and IFNλ, which was higher for the latter. 
Based on the time lag involved, this is likely to be an indirect effect, the mechanism of which 
would require additional study.  
ISGs represent the key effectors of the IFN system and as such their expression in response 
to pathogen related stimuli provides important insight into the chicken innate immune 
response. Therefore, the expression levels of four well known ISGs were measured in 
chicken splenocytes stimulated with PIC and LPS. In both cases, Mx1 and Zap showed strong 
induction that peaked at 3 h. Pkr and Viperin followed a similar trend albeit at a lower fold 
induction that failed to reach significance in the PIC stimulated cells. The pattern of ISG 
induction is in broad agreement with published data from mammal and avian in vitro 
systems, although it is clear that differences exist between cell types 223,236,267,277-279. Although 
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LPS did not induce IFNα or IFNλ it has previously been shown that IFNβ is in fact stimulated 
by LPS and responsible for the ISG upregulation 280.Treatment of splenocytes with 
recombinant IFNs revealed a difference between IFNα and IFNλ. IFNα was able to stimulate 
ISGs in a similar manner to PIC with respect to timing and breadth of genes. In contrast, IFNλ 
was only able to induce Mx1 and Viperin, reaching statistical significance at around 48 h. The 
rapid but transient induction of ISGs with IFNα but slower and more sustained induction 
with IFNλ is consistent with observations in mammals 267,271,281. It seems likely that the peak 
in ISG expression 48 h post IFNλ treatment is a consequence of the large upregulation of 
IFNs seen concomitantly at this time point, although the specificity of ISG induction would 
indicate that the effects of IFNα have been modulated in some manner. 
To provide more biologically-relevant insights, the effects of influenza virus infection were 
investigated. There studies utilized a H5N6 influenza A strain isolated from duck that was 
previously shown to elicit moderate signs of disease after 48 h. HPAI infection induced a 
significant but moderate upregulation of IFNα (8-fold) with a stronger induction of IFNλ (50-
fold) in the spleen. In the lungs, induction of IFNα was comparably higher (25-fold), with 
IFNλ upregulation comparable to the spleen (50-fold). The higher IFNα induction in the lung 
probably reflects this tissue being the primary site of infection, whereas the higher relative 
IFNλ induction in both organs is likely due the high base-line IFNα expression that reduced 
the fold change. The upregulation of both IFNs is, however, consistent with other studies 
investigating HPAI infection in birds 205,282. Moreover, the fact that both IFNs are induced 
indicates that this HPAI virus might not interfere significantly with the IFN induction, at least 
at the mRNA level. HPAI infection resulted in strong induction of Mx1 in both the spleen and 
lung, whereas Pkr was only significantly upregulated in the spleen. These expression 
patterns are consistent with the IFN induction observed as well as results in the literature 
283,284. In contrast, Zap was not significantly upregulated at the mRNA level in either the 
spleen or the lung despite previous studies showing high Zap expression that correlated with 
a shorter survival time during HPAI infections in chickens 285. The reason for this lack of Zap 
induction remains unknown. 
Substantial variability was observed in immune gene expression between birds, which 
represented a significant issue in this study. Not only did it interfere with the ability to obtain 
statistically significant results and increase bird numbers required in experiments, but also 
pointed to a biological cause. Differences in the female and male immune systems have 
previously been noted in both humans and mice 263,286-290. Exploring this as a potential cause 
of the variability of IFN expressions in chickens was interesting, since this organism has some 
51 
 
key genetic differences in this regard. In particular, the type I IFNs are located in one cluster 
on the sex (Z) chromosome of chicken, in which ZZ determines males and ZW determines 
females. Therefore, splenocytes from male or female chickens, both immature and mature, 
were tested for IFN responsiveness to PIC. Immature chicken splenocytes responded to PIC 
treatment with a time dependent activation of IFNs, and greater variability amongst 
females. For IFNα, males responded earlier, but induction in females was significantly higher 
and more sustained – a trend that also held true for IFNβ. One hypothesis for that 
observation would be that the presence of additional copies of type I IFNs in males enables a 
more rapid response. Induction of IFNλ was also earlier in males, but in this case the peak 
was significantly higher compared to females. As expected, estrogen levels were significantly 
higher in females than in males, being much more variable in the former. In mature 
chickens, induction was higher for both IFNα and IFNλ in females but only reached 
significance for IFNλ. Consistent low estrogen levels were again observed in mature males 
(around 50 pg/mL) with much higher and more variable levels in females (450-1400 pg/mL). 
Investigation of a possible correlation of estradiol levels and induction levels in mature 
females as in males showed no significant trend. Further research is required to understand 
the interactions between sex hormones and IFN responses and to identify causes of the 
observed variability of IFN induction in birds. 
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7 Characterization of chicken IFNλR  
7.1 Introduction 
Members of the Class II cytokine receptor family (CRF2) are heterodimeric receptors 
composed of two receptor subunits, denoted as R1/Rα and R2/Rβ. Each subunit is a single 
pass transmembrane protein defined by structural similarities in the extracellular domain, 
which includes the cytokine receptor homology domain (CHD) that is involved in ligand 
binding and certain sequences in the intracellular domain 164. CRF2 ligands bind with high 
affinity to the R1 chain, which characteristically has a larger intracellular domain, whereas 
the R2 chains have smaller intracellular domain and lower ligand affinities. The binding of 
the ligand to the R1 chain leads to recruitment of the R2 chain and the trimeric complex 
then initiates specific intracellular signaling cascades 164. The family is composed of 12 
distinct receptors, which are used for signaling by members of the IFN, IL-10 and IL-10 
related cytokines 164,165. Although type I and type III IFNs share similarities in biological 
activity they utilize different receptors. Unlike type I and type II IFN receptors, which signal 
through exclusive R1 and R2 subunits, IFNλR consists of the ligand specific IFNλR1 along with 
a IL-10R2, which is shared among IL-10R, IL-22R and IL-26R 119,120,166. When one of these 
chains is absent from the cell surface, or neutralized by an antibody, cells are unresponsive 
to IFNλ 119,159, showing that both IFNλR1 and IL-10R2 are needed to form a functional 
receptor complex. 
IFNλ initially binds to the IFNλR1 chain, which causes a conformational change that enables 
recruitment of the IL-10R2 to form a trimer. This activates the pre-associated intracellular 
tyrosine kinases JAK1 and TYK2 to mediate phosphorylation of the receptor chains, which 
creates docking sites for cytosolic STAT1 and STAT2 120. Signaling through type I and type III 
IFN receptor complexes results in the formation of a transcription factor complex known as 
IFN stimulated gene factor 3 (ISGF3) 128,146. This complex consists of three proteins, STAT1, 
STAT2, and IFN regulatory factor-9 (IRF-9) 120. Once assembled, ISGF3 then translocates to 
the nucleus where it binds to IFN stimulated response elements (ISREs) in the promoters of 
various interferon-stimulated genes (ISGs) 185. Despite different receptor complexes being 
employed there is a clear signaling overlap between type I and III IFNs, which is why the 
antiviral outcomes are so similar 128,146,178,185. 
Ultimately receptor expression determines which cells respond to particular IFNs. Different 
tissues and cell types have a highly specialized need to recognize, and be able to act on 
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specific signaling molecules. The IFNλR subunit, IFNλR1, is predominantly expressed on 
epithelial cells like these found in skin, lung, intestine, colon and stomach 152,159,179 but is 
undetectable in other cell subtypes, particular fibroblastic and endothelial cells. This 
contrasts with the type I IFNRs that are expressed on all nucleated cells 181. Skin and mucosal 
surfaces provide a barrier between the host and the environment which suggests that the 
type III IFN system has evolved to protect the epithelia against pathogens 159. 
The antiviral activity of type III IFNs compared to type I IFNs is reported to be ‘weaker’, 
which appears to be closely related to IFNλR1 expression 64,291. Initial studies showed that 
IFNλR1 knock-out mice were indistinguishable from the wild type mice when challenged by a 
panel of viruses, unlike IFNαR1 knock-out mice, which were highly susceptible 135,176. 
However, IFNλR1 knock-out mice were later found to be susceptible to rotavirus infection 
whereas type I IFN knock-out mice were similar to the wild type 270. 
The results from mammalian studies provides clues as to the roles of IFNs in the chicken. 
However, the identity of the IFNλR complex in chickens has not been functionally confirmed 
and its expression remains poorly characterized. In addition, downstream signaling of IFNλR 
is not documented in the avian host with few studies looking at ISG regulation. This Chapter 
aims to provide a clear picture of the IFNλR and its downstream signaling cascade to better 
understand the chicken IFNλ mediated responses. 
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7.2 Results  
7.2.1 Phylogenetic analysis of the type III IFN receptor chains 
To evaluate the extent of conservation of the type III IFNR system, a phylogenetic tree was 
constructed using the Neighbour Joining method with all published and predicted IFNλR1 
sequences (Figure 7-1). This revealed that chicken IFNλR1 clustered with those of other birds 
which were most closely related to reptile sequences that clustered together, the exception 
being the anole lizard sequence. Mammals clustered together with a significant distance 
from the bird-reptile sequences, with fish and amphibian sequences found to be more 
distantly related. Closer analysis of the bird sequence cluster showed the chicken sequence 
was most closely related to that of turkey, duck and goose. 
Phylogenetic analysis of IL-10R2 sequences gave a tree with similar topology (Figure 7-2). 
Bird sequences again clustered and were most closely related to reptile sequences. Mammal 
sequences clustered together in a tight group, with amphibians and Carolina anole between 
birds and mammals and fish sequences the most distant. Closest related to the chicken 
sequence were those of turkey, duck and goose. 
7.2.2 Synteny of genes encoding the type III IFN receptor chains 
To provide evidence of orthology the conservation of flanking genes was investigated. The 
human IFNλR1 gene is located on chromosome 10 and is flanked by the MYOM3 and IL-22RA 
genes upstream and the GRHL3, STPG1, NIPAL3 and RCAN3 downstream (Figure 7-3A). The 
chicken gene was found to be located on chromosome 23 with the predicted upstream 
flanking genes also MYOM3 and IL-22RA and the downstream genes GRHL3, NIPAL3 and 
RCAN3. Both the chicken and human IFNλR1 genes consist of 7 exons.  
The human IL-10R2 is located in the IFN receptor cluster on chromosome 21 and is flanked 
by IFNαR2 upstream and IFNαR1 and IFNγR2 downstream (Figure 7-3B). The chicken 
orthologue was also found to be located in the IFN receptor cluster on chicken chromosome 
1 and was flanked by IFNαR2 upstream and IFNαR1 and IFNγR2 downstream. The chicken 
and human IL-10R2 also consisted of 7 exons. This suggests both genes are orthologous with 
their human counterpart. 
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Phylogenetic tree of all IFNλR1 protein sequences constructed using the Neighbor-Joining 
method. The tree is drawn to scale, with branch lengths in the same units as those of the 
evolutionary distances used to infer the phylogenetic tree.  The insert shows the closest 
relatives to the chicken sequence in the avian clade. 
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Figure 7-1 Phylogenetic analysis of IFNλR1 proteins 
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Phylogenetic tree of all IL-10R2 protein sequences constructed using Neighbor-Joining 
method. The tree is drawn to scale, with branch lengths in the same units as those of the 
evolutionary distances used to infer the phylogenetic tree. The insert shows the closest 
relatives of the IL-10R2 gene in the avian clade.  
Figure 7-2 Phylogenetic analysis of IL-10R2 proteins 
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(A) Location of the human IFNλR1 gene on chromosome 10 and the chicken IFNλR1 gene on 
chromosome 23 . The flanking regions show conserved genes upstream (MYOM3, IL-22R1) 
and downstream (GRHL3, NIPAL3 and RCAN 3. The predicted gene structure of chicken 
IFNλR1 shows seven exons and six introns like human IFNλR1. (B) Location of the human IL-
10R2 on chromosome 21and the chicken IL-10R2 on chromosome 1. Conserved flanking 
genes upstream (IFNαR2) and downstream (IFNαR1, IFNγR2) genes are shown. The IL-10R2 
gene has seven exons and six introns in both species.  
Figure 7-3 Synteny of IFNLR1 and IL10R2 
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7.2.3 Tissue distribution of the type III IFN receptor chains 
To gain insight into the role of the IFNλR complex, its tissue distribution was evaluated. Total 
RNA was isolated form chicken tissues and purified mononuclear cells from the bone 
marrow and blood and subjected to qRT-PCR to assess the expression of the genes encoding 
the two IFNλR chains (Figure 7-4) with the relative expression levels calculated using GAPDH 
as a housekeeping gene. Assuming comparable amplification efficiency, the expression of 
IFNλR1 was universally lower than that of IL-10R2 in all the tissue types. The highest IFNλR1 
expression was seen in the spleen, bursa and particularly PBMCs. The lowest expression of 
both receptors was found in the brain. To provide additional perspective the relative 
receptor chain expression was analyzed. The ratio of IL10R2 to IFNλR1 was found to be 5-
fold in spleen, bone marrow and bursa, around 3-fold in the thymus and 7- and 15-fold in 
PBMCs and brain respectively. 
7.2.4 Functional analysis of the chicken type III IFN receptor complex 
While there was good circumstantial evidence that a functional chicken IFNλR complex 
existed, to provide definitive support a siRNA knockdown strategy was developed in the 
chicken fibroblast cell line (DF1). Chicken IFNλR specific siRNA (Figure 7-5A) was able to 
knockdown IFNλR1 mRNA expression by 60% at 48 h post transfection compared to the non-
target control siRNA (eGFP). Similarly, a IL-10R2 siRNA (Figure 7-5B) resulted in an 80% 
knockdown of IL-10R2 gene expression compared to an eGFP siRNA treated control. These 
cells were subsequently stimulated with chicken IFNλ (chIFNλ) and analyzed for STAT 
activation by EMSA (Figure 7-6) and Mx1 gene expression by qRT-PCR (Figure 7-7) as a 
measure of receptor activation. Strong STAT activation was observed in the control group, 
which was greatly reduced in the IFNλR1 siRNA group and almost undetectable in the IL-
10R2 siRNA treated group. Similarly, significantly lower expression level of Mx1 was 
observed post IFNλ stimulation in both the IFNλR1 siRNA and the IL-10R2 siRNA treatment 
groups, respectively, when compared to the eGFP (non-target) siRNA treated group.  
To verify that the signal downstream of the chicken IFNλR complex utilized JAK1, the 
selective JAK1 inhibitor Ruxolitinib, was employed. Stimulation of DF1 cells with chIFNλ led 
to a significant upregulation of Mx1 from the unstimulated state while the cells treated with 
Ruxolitinib and chIFNλ showed no upregulation (Figure 7-8).   
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Figure 7-4 Tissue distribution of IFNλR chains 
Expression of IFNλR1 and IL-10R2 mRNA in tissues and cell populations of 6-week old SPF 
chickens. Relative expression levels of IFNλR1 (white dots) and IL-10R2 (black diamonds) 
normalized against the housekeeping gene GAPDH. IFNλR1/IL-10R2 ratio in each tissue are 
indicated by blue squares. 
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Figure 7-5 Confirmation of successful siRNA mediated gene knockdown  
Expression of IFNλR1 (A) and IL-10R2 (B) mRNA in DF1 cells treated with the respective 
siRNAs and a non-target control siRNA (eGFP). The bars represent relative expression levels 
of mRNA, normalized against the housekeeping gene GAPDH as a percentage of expression 
compared to the control. (**** p value < 0.0001 compared using Students t test). 
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Figure 7-6 Effect of IFNλR chain knockdown on STAT activation 
EMSA analysis of STAT activation following IFNλ stimulation of DF1 cells with no siRNA (-) or 
transfected with IFNλR1 siRNA or IL-10R2 siRNA as indicated in duplicates. Red box indicates 
the stat complexes, NS indicates nonspecific bands, FP indicates free probe. 
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Figure 7-7 Effect of IFNλR chain knockdown on Mx1 expression 
Expression of Mx1 mRNA in DF1 cells treated with siRNAs targeting IFNλR1 (black), IL-10R2 
(white) or control siRNA (eGFP). The bars represent relative expression levels of mRNA, 
normalized against the housekeeping gene GAPDH as a percentage of expression compared 
to the control. (**** p value < 0.0001 compared using a one-way ANOVA test with 
uncorrected Fischer LSD post-test). 
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Figure 7-8 Effect of JAK inhibition on IFNλ-mediated Mx1 induction 
Expression of Mx1 mRNA in untreated and unstimulated (grey), untreated and IFNλ 
stimulated (white) and Ruxolitinib-treated and IFNλ stimulated (black) DF1 cells. The bars 
represent fold change in levels of mRNA expression, normalized against the housekeeping 
gene GAPDH compared to the untreated/unstimulated group. (**** p value < 0.0001 using a 
one-way ANOVA test with Bonferroni posttest). 
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7.3 Discussion 
Translated IFNs are transported out of the cell and stimulate cell surface IFN receptors 164. 
For IFNλ, the receptor complex comprises IFNλR1 and IL-10R2 , which relays the signal 
through the intracellular JAK-STAT pathway 118,119. Type I and type III IFNs stimulate highly 
similar biological effects largely through their shared downstream signaling components 
JAK1 and TYK2, which phosphorylate and activate STAT1/STAT2 heterodimers that associate 
with IRF9 to form the transcriptional complex ISGF3 292. ISGF3 upregulates the expression of 
hundreds of antiviral genes that block the virus lifecycle at multiple stages 207. The IFNλ 
mediated signaling cascade has been very well characterized in mouse and human but little 
is known about this pathway in chicken. The IL-10R2 was previously characterized and a 
candidate IFNλR1 gene had been identified using BLASTN. However, confirmation of the 
identity of this candidate gene and the dependency of both chains for chicken IFNλ signaling 
via the JAK/STAT pathway was missing. 
The human IFNλR1 gene has 7 exons and is flanked upstream by MYOM3 and IL-22RA genes, 
and downstream by GRHL3, STPG1, NIPAL3 and RCAN3 genes. The candidate chicken IFNλR 
gene showed identical synteny except for STPE1 for which no chicken homologue could be 
identified. As shown previously by Reboul et al 202 the structure and location of the second 
receptor chain gene, IL-10R2, is conserved between chicken and human consisting of seven 
exons and is located in an IFN receptor cluster, flanked upstream by IFNαR2 and 
downstream by IFNαR1 and IFNγR2.  
Phylogenetic analysis of the IL-10R2 and IFNλR1 chains revealed that both chicken 
sequences clustered with those from other birds. These were collectively most similar to 
reptiles, which is expected given their shared evolutionary history 293. For both receptor 
chains, mammalian sequences clustered tightly together at a significant distance from the 
avian-reptilian sequences. Fish sequences were found to be the most distant in this analysis, 
consistent with other published work 56. 
Expression of both IFNλR chains was investigated in immune relevant tissues to identify 
those likely to be responsive to IFNλ in the chicken. In all tissues examined, IL-10R2 was 
more highly expressed than IFNλR1. The highest IFNλR1 expression levels were observed in 
splenic, bursal tissues and PBMC; similar to results observed in humans 172. Interestingly 
purified splenocytes showed even higher IFNλR1 expression than the whole spleen which 
may indicate increased expression of IFNλR1 by white blood cells (data not shown). The 
highest IL-10R2 expression was in the brain followed by PBMCs, spleen, bone marrow and 
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bursal tissue, and the lowest thymic tissue. As both chains must be present for an IFNλ-
mediated immune response these findings indicate that the IFNλR1 is likely the restrictive 
receptor as it is universally expressed at a lower level. Although the levels of expression 
were only investigated at the level of mRNA, previously published work has shown a direct 
correlation between IFNλR mRNA expression and responsiveness to chIFNλ 206.  
Two chicken cell lines were tested for IFN λR1 expression and both the Fibroblastic cell line 
DF1 and the Macrophage cell line HD11 were found to express low levels of the receptor, 
however as the transfection efficiency was higher in DF1s the work was continued with 
these cells. An siRNA mediated knockdown strategy was used to target both IFNλR chains 
separately. This blunted chIFNλ-induced STAT activation and Mx1 expression by up to 60% 
compared to controls which corresponded with the knockdown efficiency of the respective 
siRNAs. The involvement of JAK1 was examined with Ruxolitinib, a selective JAK1 inhibitor 
used as a treatment for myelofibrosis 294. DF1 cells treated with chIFNλ showed a 6-fold 
increase in Mx1 mRNA levels, which was completely blocked with Ruxolitinib. These results 
collectively confirm that chIFNλ requires IFNλR1, IL-10R2 and JAK1 for STAT complex 
activation and the subsequent upregulation of ISGs like Mx1. 
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8 Characterization of chicken IFIT5  
8.1 Introduction 
Avian influenza (AI) viruses, especially the highly pathogenic subtypes, cause significant 
morbidity and mortality in chickens worldwide 237. This has widespread consequences, 
notably including severe economic losses 239 and the potential of zoonotic transmission to 
humans 237,241-243. To fully understand how the disease might be combatted in poultry it is 
essential to characterize the parts of the host immune system responding to influenza virus 
infection 248. 
The innate immune system forms a critical part of the host defence against pathogens and 
several pathways have been characterized to date. In mammals, innate immune recognition 
is mediated by a series of germ-line encoded receptors called pathogen recognition 
receptors (PRR) that detect conserved pathogen-associated molecular patterns (PAMPs) 40. 
One of the most prominent families of PRR are the Toll-like receptors (TLR) 41. To date, nine 
conserved TLRs have been found in humans and mice and each one serves a distinct function 
in PAMP recognition and immune response 53. TLRs essentially function as sentinels, which 
when activated modulate the expression of multiple immune genes that are involved in the 
mobilization of a wider immune response 38,44. Infections with viral pathogens may be 
sensed through TLR3, which recognizes double stranded RNA (dsRNA) and TLRs 7, 8 and 9, 
which recognize non-self nucleic acids 45-50. Upon viral PAMP engagement, TLRs trigger 
intracellular signaling cascades that lead to the expression of a variety of pro-inflammatory 
cytokines and chemokines as well as antiviral genes, which together orchestrate the early 
host response to infection 53,295. However, important differences between the mammalian 
and the avian hosts have been found like the absence of TLR9 and RIG-1, while chicken TLR8 
seems to be non-functional. Notwithstanding this, TLR3, the most important receptor in 
dsRNA sensing has been found and characterized 261,296,297. Furthermore, there is evidence to 
suggest that chicken MDA5 is also a functional analogue of mammalian RIG-1 255. 
Cytokines comprise a large family of molecules, including interferons (IFNs), interleukins 
(ILs), colony-stimulating factors (CSFs), transforming growth factors (TGFs) and tumour 
necrosis factors (TNFs) 58. It is now recognized that several IFNs are collectively crucial for 
defence against viral pathogens, contributing to the induction and regulation of both innate 
and adaptive antiviral mechanisms 61-63. Three distinct interferon families, type I , II and III, 
have been identified in mammalian and avian species, which differ in their amino acid 
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sequence, receptor specificity, signaling pathways and gene induction, but there is overlap 
between families 64-66. Although only type I and III IFNs are directly produced in response to 
viral infections, all types significantly contribute to the generation of an effective antiviral 
immune response against a wide range of pathogens 59. This is achieved by upregulation of 
hundreds of antiviral genes that act in concert to limit viral spread and replication 207, which 
includes members of the IFIT family. Human and mouse IFIT1-5 have been shown to play 
critical roles in antiviral defence 211. The mechanisms are not completely understood but 
IFIT1 and IFIT2 have been shown to suppress translation by binding to the eukaryotic 
initiation factor 3 211. IFIT family members can also bind to single stranded RNA 211,227 and 
double stranded DNA 228 directly and thereby reduce viral replication. 
A better understanding of the innate immune system particularly in acute AI infection is 
needed for the development of targeted therapeutic interventions. In this Chapter the IFIT5 
gene of chickens was investigated to gain further insights into the innate defence of this 
important production animal against viral pathogens. In particular, the response of the 
chicken IFIT5 gene to different immune stimuli and acute influenza virus infection was 
assessed.  
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8.2 Results 
8.2.1 Identification and characterization of a putative chicken IFIT5 gene 
Bioinformatic analysis of the chicken genome with the human IFIT5 gene sequence using 
BLASTN identified a potential chicken IFIT5 gene located on chromosome 6 (Figure 8-1). It 
was flanked by CH25H and LIPA upstream and SLC16A and PANK 1 downstream, similar to 
the human IFIT gene cluster located on chromosome 10. Like human IFIT5, the chicken gene 
also consisted of 2 exons and 1 intron. 
Gene specific primers were used to amplify cDNA from 4-week old White Leghorn chicken 
splenocytes stimulated with poly (I:C) for 3 h. This generated an approximately 1440 base 
pair (bp) amplicon (Figure 8-2) that was not observed in the no template control. This 
amplicon was cloned and sequenced (Accession No.: KT180229) revealing nine single 
nucleotide polymorphisms (SNPs) when compared to the predicted sequence, five of which 
would lead to amino acid changes in the 470 residue protein.  
8.2.2 Conservation of chicken IFIT5 
Phylogenetic analysis of IFIT protein sequences (Figure 8-3A) showed that the putative 
chicken IFIT5 clustered with similar genes from other bird species as well as from turtle. In 
contrast, mammalian sequences clustered together in distinct families of IFIT1-5 with the 
exception of chimpanzee IFIT3 and marsupial IFITs, which formed their own clade. Fish 
sequences were the most distantly related and formed two distinct clades, with reptile 
(lizard) and amphibian (frog) sequences in between. To illustrate the sequence divergence of 
bird IFITs compared to human IFIT1-5 a smaller tree was constructed (Figure 8-3B). The 
chicken IFIT5 protein sequence clustered with the other bird IFITs, whereas the human 
sequences formed a separate clade. Chicken IFIT5 was most closely related to the turkey 
IFIT5 sequence with 0.10 amino acids substitutions per site (aas/s) (Table 1) followed by the 
recently cloned duck IFIT5 298 with 0.47 aas/s. Of the human IFIT proteins, the chicken IFIT5 
was most closely-related to human IFIT5 with 0.89 aas/s and IFIT1B with 0.92 aas/s. Domain 
prediction of the chicken IFIT5 protein sequence identified multiple Tetratricopeptide 
repeats (TRPs), a hallmark of IFIT genes, with an arrangement of TRPs similar to other bird 
and human IFIT genes (Figure 8-4A). Protein sequence alignment with human IFIT5 (Figure 
8-4B) revealed that 13 out of 16 amino acids previously shown to be critical for function 
were conserved in chicken IFIT5, including two residues that were important for 
ssRNA/dsDNA binding selectivity 228.  
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Figure 8-1 Chromosomal location and predicted gene structure of chicken IFIT5 
Location of the chicken IFIT5 gene on chromosome 6 and the human IFIT5 gene cluster on 
chromosome 10. Conserved flanking genes upstream (CH25H, LIPA) and downstream 
(SLC16A, PANK1) and additional human IFIT genes are shown. The predicted gene structure 
of chicken IFIT5 with 2 exons and one intron is presented.   
 
 
Figure 8-2 Amplification of the chicken IFIT5 gene 
RT-PCR amplification of the ~1440 bp chicken IFIT5 gene using specific primers from poly 
(I:C) stimulated splenocytes (+). No amplification was observed when the template was 
omitted (-). 
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Table 1 Evolutionary distance of homologs from chicken IFIT5 gene 
The number of amino acid substitutions per site from between sequences are shown. 
Analyses were conducted using the JTT matrix-based model. The analysis involved 10 amino 
acid sequences. All positions with less than 85% site coverage were eliminated. The analyses 
were conducted in MEGA 7. 
Chicken IFIT5                   
Turkey IFIT5* 0.10                 
Duck IFIT5 0.47 0.47               
Flycatcher IFIT5* 0.67 0.66 0.66             
Zebrafinch IFIT5* 0.65 0.62 0.60 0.33           
Human IFIT1 0.98 0.99 0.99 1.04 1.01         
Human IFIT1B 0.92 0.95 0.97 1.02 0.97 0.40       
Human IFIT2 1.23 1.22 1.18 1.19 1.18 0.93 0.98     
Human IFIT3 1.26 1.22 1.22 1.30 1.25 0.98 0.93 0.58   
Human IFIT5 0.89 0.92 0.90 1.00 0.94 0.58 0.64 0.95 0.98 
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Figure 8-3 Phylogenetic analysis of IFIT5 proteins 
(A) Phylogenetic tree of all IFIT published protein sequences using constructed the Neighbor-
Joining method. The tree is drawn to scale, with branch lengths in the same units as those of 
the evolutionary distances used to infer the phylogenetic tree. (B) Predicted evolutionary 
history of the indicated human and bird IFIT proteins constructed using the Maximum 
Likelihood method. Bootstrap values are shown at the nodes as a percentage of 1000 
replicates. The scale bar represents 0.1 aa substitutions per site.  
A 
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Figure 8-4 Domain analysis of human and avian IFITs 
(A) Schematic representation of the predicted Tetratricopeptide repeats (TRP) domains 
within the indicated IFIT protein sequences (* denotes predicted sequences). Numbers on at 
the end of each sequence indicates protein length. (B) Alignment of chicken and human IFIT5 
sequences. Numbers above the sequence denote bp from the start of the aligned sequence, 
dashes mark gaps in the alignment, and stars indicate the end of sequence. Residues 
identified as functionally critical in humans are highlighted 
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8.2.3 Expression of chicken IFIT5 following immune stimulation 
To further characterize the chicken IFIT5 gene, its expression in response to immune stimuli 
was investigated. Some ISGs can be induced by TLR pathways independently of IFN. To 
assess this chicken splenocytes were treated with 50 μg/mL poly (I:C) (Figure 8-5A) and 10 
μg/mL LPS (Figure 8-5B) and the expression of IFIT5 and the well-known chicken Myxovirus 
resistance protein 1 (Mx1) gene quantified. The poly (I:C) treatment up-regulated both IFIT5 
and Mx1 expression, which peaked at 6 h post stimulation at ~90- and 100-fold, respectively. 
LPS stimulation induced a 15-fold increase in IFIT5 expression from 6-24 h post stimulation 
followed by a rapid decline to undetectable levels at 48 h, with a similar pattern of Mx1 
induction observed. 
The interferon inducible nature of mammalian IFITs has been well characterized. To confirm 
that IFIT5 is an ISG, splenocytes from SPF chickens were treated with recombinant chicken 
IFNα (Figure 8-6A) and IFNλ (Figure 8-6B). Following IFNα treatment, IFIT5 was rapidly 
induced reaching significant levels at 1.5 h with peak expression at 3 h at 75-fold, Mx1 
induction was delayed, peaking at 6 h at 45-fold. Both IFIT5 and Mx1 expression remained 
significantly above base-line until 24 h followed by a decrease at 48 h. Following IFNλ 
stimulation there was a steady increase in IFIT5 expression with the highest increase in 
expression of around 25-fold at 48 h post treatment. Mx1 behaved similarly although the 
fold induction was lower with an approximate 10-fold increase in mRNA levels at 3 h.  
8.2.4 Expression of chicken IFIT5 following viral infection 
Since IFIT5 is considered an antiviral gene it was important to also characterize the gene 
expression levels in response to acute infection in vivo. Therefore, the expression of IFIT5 
and Mx1 was measured in spleen (Figure 8-7A) and lung (Figure 8-7B) of H5N6 virus-infected 
SPF chickens. Both IFIT5 and Mx1 were upregulated approximately 400-fold in the lungs and 
60-fold in the spleen of infected birds compared to healthy age-matched chickens. 
Since eggs are universally used to amplify influenza virus the expression of these genes was 
also assessed in eggs infected with an H1N1 Influenza A virus (Figure 8-8). IFIT5 was 
upregulated at 24 h post infection reaching significance at 48 h in the CAM, while in muscle 
and brain no expression was detected at 24 h but expression was observed at 48 h. Mx1 
behaved similarly in the CAM although did not reach statistical significance. Mx1 expression 
in the muscle was upregulated at 24 h with a significant increase at 48 h, while the brain 
showed no induction at 24 h but increased Mx1 mRNA was detected at 48 h post infection. 
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Figure 8-5 Expression of IFIT5 and Mx1 in response to TLR agonists 
Expression of IFIT5 and Mx1 mRNA in splenocytes from SPF chickens stimulated with 50 
μg/mL poly (I:C) (A) and 10 μg/mL LPS (B). This is shown as mean fold change with standard 
error of the mean (SEM) compared to the untreated sample, normalized against the 
housekeeping gene GAPDH (* p value < 0.05, ** p value < 0.005, *** p value < 0.001 **** p 
value < 0.0001 compared to the 0 h time point using a one-way ANOVA test with 
uncorrected Fischer LSD post-test). The Mx1 data is a duplicate of that already shown in 
6.5A/B and serves as a comparison. 
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Figure 8-6  Expression of IFIT5 and Mx1 in response to IFN stimulation 
Expression of IFIT5 and Mx1 mRNA in splenocytes from SPF chickens stimulated with 500 
ng/mL IFNα (A), 50 μg/mL IFNλ (B). This is shown as mean fold change with standard error of 
the mean (SEM) compared to the untreated sample, normalized against the housekeeping 
gene GAPDH (* p value < 0.05, ** p value < 0.005, *** p value < 0.001 **** p value < 0.001 
using a one-way ANOVA test with uncorrected Fischer LSD post-test). The Mx1 data is a 
duplicate of that already shown in 6.6A/B and serves as a comparison.   
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Figure 8-7 Expression of IFIT5 and Mx1 in response to viral infections in vivo
Expression of IFIT5 and Mx1 mRNA in six 5-week old SPF chicken spleen (A) and lung (B) at 
22 h post infection with Influenza virus A/duck/Laos/XBY004/2014 (H5N6). Bars represent 
the mean fold change of mRNA expression with SEM compared to the same tissue of the 
uninfected birds, normalized against the housekeeping gene GAPDH (* p value < 0.05 using 
the Students t test with Mann Whitney U test). The Mx1 data is a duplicate of that already 
shown in 6.8A/B and serves as a comparison.  
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Figure 8-8 Expression of IFIT5 and Mx1 in response to viral infections in ovo 
Expression of IFIT5 (A) and Mx1 (B) mRNA in D10 embryonated chicken eggs 24 h and 48 h 
post infection with Influenza virus A/Puerto Rico/8/1934 (H1N1). Bars represent the mean 
fold change of mRNA expression with SEM compared to the same tissue of uninfected eggs, 
normalized against the housekeeping gene GAPDH (* p value < 0.05, ** p value < 0.005, 
using a one-way ANOVA test with uncorrected Fischer LSD post-test). 
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8.3 Discussion 
The IFIT family of proteins is found across diverse species 211,299. However, the mode of 
action of these proteins is not well understood. In avian species, even less is known, with 
only limited recent transcriptome studies characterizing their expression profiles 231,300,301. 
The identification and characterization of chicken IFIT5 allows for further in-depth 
investigation of its role in avian immunity, including in response to virus. Bioinformatic 
analysis was used to identify the genes and determine its location and structure. The chicken 
IFIT5 gene was located on chromosome 6, flanked by the CH25H and LIPA genes upstream 
and SLC16A and PANK1 downstream, which revealed conserved synteny with human and 
other species 211. It also consisted of 2 exons and 1 intron like in other species, which 
strongly suggests common derivation. The chicken IFIT5 was shown by RT-PCR to be 1440 bp 
in length, encoding a protein of 470 amino acids, which is consistent with mammalian and 
other avian IFIT proteins investigated. Ten SNPs were identified (Figure 11-2, Appendix) of 
which five were silent and five were missense mutations (Figure 11-3, Appendix). SNPs in the 
IFIT5 gene have been described in humans and other species 211 and could be explained by 
genetic diversity, in this case variations between individual birds, which may be even greater 
between chicken breeds 302.  
Phylogenetic analysis showed that the bird sequences clustered together but were related to 
mammalian IFITs. These findings followed the general trend for IFIT genes to cluster with 
their own class rather than paralogues in other classes, which makes definitive identification 
of orthology difficult based on sequence alone. Further analysis of the chicken IFIT5 protein 
sequence indicated it was closely related to other bird IFITs and amongst the human IFIT 
family was most similar to human IFIT5 with 0.89 aa substitutions per site. Protein sequence 
alignment and domain prediction analysis revealed conservation of the Tetratricopeptide 
domains that are the hallmarks of IFITs compared to other bird and human IFITs 211,299.  
The crystal structure of the human IFIT5 protein has been solved and aa critical to the 
function of IFIT5 identified by non-conserved site-directed mutagenesis 228. Of the 16 critical 
aa identified, 13 were conserved in the chicken sequence. Amongst the three non-conserved 
critical aa only one was associated with a decrease in binding affinity to nucleic acids in the 
human protein, the other two only showed a decrease in tandem with another mutation 
site. Importantly, the sites that determined substrate specificity to ssRNA or dsDNA (F284 
and R294 in humans) were found to be conserved in the chicken sequence, suggesting that 
IFIT5 can bind to both substrates, although possibly with reduced binding affinity.  
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The robust induction of IFIT genes in response to immune stimulation and concomitant 
antiviral function is well established in mammalian systems 303. A similar strong induction of 
IFIT5 was observed following stimulation of chicken splenocytes with the TLR agonist poly 
(I:C). Upregulation of mRNA expression started at 3 h and peaked at 6 h post stimulation, 
which is consistent with observations made in human cells 304, and with similar kinetics to 
the Mx1 gene, one of the best characterized ISGs in chicken 220. The TLR4 ligand, bacteria-
derived LPS, also induced significant increase for IFIT5 and Mx1 mRNA after 6 h treatment. 
The induction of IFIT5 started at 3 h and was still significant at 24 h and elevated at 48 h 
consistent with previously reports observing in human macrophages and neutrophils 278,279. 
Whether this effect was due to direct transcriptional stimulation or indirectly via the IFN 
pathway is unclear at this point although it has been proposed that IFITs can be induced 
directly via PRRs 303. Treatment of splenocytes with IFNα led to a significant upregulation of 
IFIT5 after 1.5 h with a peak at 3 h that remained high until 24 h, whereas Mx1 was more 
delayed and reached significant upregulation at 3 h peaking at 6 h post stimulation followed 
by a decline. IFNλ treatment led to a much slower increase, peaking at 48 h post treatment. 
Although different in kinetics, the ability of both type I and type III IFNs to induce IFITs 
clearly demonstrated the interferon stimulated nature of the chicken IFIT5 gene. 
During viral infection, IFITs bind to viral RNA and host factors needed for viral replication and 
thereby limit viral growth 211,303. In chickens, some of the most devastating infections are 
caused by highly pathogenic avian influenza A viruses of the H5 and H7 subtypes. To 
determine if the identified IFIT homolog was potentially involved in the host response to this 
agent lung and spleen samples were analyzed from birds infected with HPAI virus (H5N6). 
These tissues were selected as representatives of the primary site of infection (lung) and the 
subsequent immune response (spleen). A significant upregulation of IFIT5 mRNA was 
observed in both the lung and spleen of infected birds compared to uninfected controls. 
Little is known about the antiviral defense in chicken eggs despite their wide use as virus 
substrate and so this was investigated.  
Both HPAI viruses A/duck/Laos/XBY004/2014 (H5N6) and A/Vietnam/1194/2004 (H5N1) 
resulted in the death of the embryo within 24 h of infection, this made sampling of the 
tissues impossible and a low pathogenic strain was chosen to give more consistent results. 
The H1N1 infection of eggs led to the induction of IFIT5 in the CAM after 24 and 48 h while 
significant induction of Mx1 was observed in the muscle. This confirms that IFIT5 expression 
is highly upregulated during active infection in chicken and might have a critical role.  
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9 General Discussion 
HPAI represents a serious problem, that impacts us on multiple levels. These viruses can lead 
to severe economic losses, potential bottlenecks in vaccine production and food shortages. 
Some of the H5 and H7 strains can also infect humans through bird-human transmission and 
cause high mortality rates with the potential for pandemics 28,30. 
Vaccination is the most efficient way to prevent viral spread through populations, although 
the genetic instability of Influenza viruses makes this a continuous effort with new vaccines 
annually based on circulating virus strains 305-307. There vaccines provide a good level of 
protection, but they are not always efficient against emerging viruses 242. Vaccination 
chicken populations with seasonal as well as emerging HPAI strains has so far proven 
successful in keeping the burden of disease down but is not enough to prevent further spill 
over 308. Moreover, the key reservoir, the wild aquatic bird population, cannot be vaccinated 
308. 
Another strategy to counter HPAIs are antiviral therapies which have been successfully 
deployed in acute cases of human Influenza infection. However, despite multimillion dollar 
compound screening enterprises 309-312. The treatment of birds remains problematic and 
would no doubt lead to resistance of these viruses and negate any beneficial effect for 
humans in the long run as seen with Relenza in recent years 313-315.  
An alternative strategy to combat HPAI viruses and so protect the human population and the 
food and vaccine supply, is to focus on disease resistance in the transmission host. In most 
human HPAI infection the source of infections can be traced back to chickens, which have 
severe reactions and, in case of some HPAI strains, die within 24-48 h 316. The timeframe 
suggests that these birds are not able to contain the viruses in the first stages of infection, 
indicating inappropriate innate immune response. In order to develop strategies making 
chickens resistant to these HPAI strains, it is necessary to understand chicken innate 
immunity in order to identify in which part of the immune response fails to respond in an 
appropriate manner. 
The first line of defence against viruses are the IFNs, which were incidentally discovered in 
chicken eggs 60 years ago 60. Greater understanding of these important mediators of innate 
(and adaptive) immunity could lead to insight into the issues around the high mortality rates 
and severe disease outcomes in birds. Although all IFN types contribute to the antiviral 
immune response only type I and type III are directly antiviral 59. Due to the very short 
79 
 
window between infection, diseases onset and death the focus was on IFNα, the oldest and 
best characterized antiviral IFN 60, and IFNλ 119,120 , the newest member of the IFN family. 
IFNαs has been well characterized in all model species as well as the chicken, while 
information on IFNλ in mammals is rapidly emerging. Nonetheless it was of considerable 
importance to study chicken IFNλ function in more detail as mice and human data are not 
directly applicable due to their multiple variants, IFNλ1,2,3 and 4 showing distinctive 
functions as reported by a myriad of studies. Which of these are shared by chicken IFNλ 
remains unclear, although sequence comparison suggests IFNλ2 201 is the most highly 
related. This study has identified similarities between IFNα and IFNλ but also distinct 
differences, which highlights important non-redundant roles of IFNλ in the antiviral immune 
response in chickens.  
Host receptors such as TLRs 44, RLRs 317 and NLRs 318 detect the presence of pathogens to 
trigger the interferon-mediated immune response. Compared to their mammalian TLR 
counterparts, chicken TLR8 is non-functional and TLR9 and RIG-1 are absent. However, TLR3, 
the most important receptor in dsRNA detection, appears to be present and functional 
261,296,297. Furthermore, there is evidence to suggest that chicken MDA5 is also a functional 
analogue of mammalian RIG-1 255. Chicken cells were found to respond to the foreign RNA 
mimic PIC with significant IFNα and IFNλ upregulation even at low doses. IFNλ showed a 
greater fold induction, but this is probably best explained as a consequence of the relatively 
high baseline expression of IFNα, which makes the fold change comparably low. In fact, the 
high baseline IFNα expression has been linked to eliciting an efficient response to viral 
triggers 319. PIC-dependent IFNα induction was more consistent whereas IFNλ induction was 
highly variable. Despite this, the expression of both genes followed the same kinetics, 
peaking after 3-6 h post stimulation with PICs, which is comparable to mammalian systems 
257,271. LPS, on the other hand, did not upregulate IFNα or IFNλ at any time point. Human 
studies suggest that only IFNλ1 can respond to LPS stimulation but not IFNλ2 or IFNλ3. 
Collectively, this data suggests a common PRR mediated induction pathway with these IFNs. 
In contrast, IFN mediated induction of the IFNs was markedly different. IFNα induced IFNα 
expression shortly after stimulation, but not IFNλ. IFNα also induced peak ISG expression 
after 6 h, although whether that is a direct result of PIC stimulation or indirect through the 
IFNs produced is unknown. In contrast, the IFNλ mediated ISG induction took place at 48 h 
and so likely indirect, which was also observed in DF1 cells (data not shown) and reportet in 
human cells 320. The altered ISG expression kinetics is suggestive of a non-redundant role in 
immune regulation. 
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The high level of variance observed in experiments examining IFN and ISG expression levels 
led to the investigation of possible causes. Differences between the male and female 
mammalian immune systems have been a field of discussion in scientific literature 289,290,321-
324. This is of particular relevance in chickens since the type I IFNs are located on the sex 
chromosome (Z). Moreover, in contrast to sex determination in mammals, male chickens are 
determined but two copies of this chromosome (ZZ) and females by one (ZW). This means 
that males have additional copies of these genes. Despite this, PIC stimulation of purified 
splenocytes resulted in a significantly higher expression of type I IFNs in females compared 
to age-matched males. IFNλ expression, on the other hand, was significantly higher in males 
than females. In mature chickens both type I and type III IFNs showed higher expression 
levels in female, although only IFNλ reached significance. Higher expression of IFNα in 
female DCs has previously been reported and was linked to the relative expression levels of 
IRF5 324. The influence of estrogen was investigated as a possible explanation but no direct 
correlation between estrogen levels and IFN expression was observed in individual birds 
although, the estradiol levels were, as expected, significantly higher females than in males. 
These data do, however, confirm that female and male birds differ significantly in the 
magnitude of antiviral response, which provides one explanation for the fluctuations in IFN 
and ISG induction observed. More research into whether gender differences and other 
potential sources of variance between birds observed are warranted. This could have 
important implications for the chicken industry as layers are naturally female and broilers 
universally male. Understanding the differences in immune response could lead to 
alternative strategies to prevent or treat infection between those populations.  
Receptor expression represents one major control point in tailoring IFN signaling to specific 
cells 325 as well as the magnitude of the signal relayed 118. A chicken IFNλR1 candidate was 
characterized and found to cluster with other birds and reptiles, while mammalian 
sequences clustered together and those from amphibians and piscine species clustered 
further away. A similar result was found for IL-10R2. This suggests a functional IFNλR 
complex was present before avian/mammalian divergence, and has been maintained in both 
lineages, indicative of important conserved functions in both lineages. 
The tissue distribution of IFNλR complex components was investigated, with a focus on 
immune relevant tissues. In mammals it is primarily found in epithelial cells but recently 
evidence has emerged that IFNλ acts on endothelial cells of the blood-brain barrier 180. 
Chickens are anatomically very different from mammals with regard to immunity. Chickens 
lack lymph nodes and so the spleen is an especially important organ involved in pathogen 
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defence. The thymus is the main organ for T(hymus) 326 cell development while the Bursa of 
Fabricius hold the B(ursa) 327 cell compartment. All tissues investigated expressed the IL-
10R2 chain in relatively high levels, with the ratios of IFNλR1 and IL-10R2 always heavily 
skewed in favor of IL10R2, which suggests that IFNλR1 levels are the limiting factor. 
However, recently the potentially variable expression of GAPDH across the tissues has been 
documented could lead to false conclusions 328. The highest expression of the IFNλR1 chain 
was observed in PBMCs followed by the spleen, bursa, thymus and the bone marrow, while 
brain tissue had the lowest expression. Purified chicken splenocytes showed higher IFNλR1 
expression relative to the whole tissue. This data suggests that immune reactive tissues tend 
to express IFNλR1, while immune privileged tissues like the brain do not. An IFNλ-mediated 
effect on immune cells is therefore highly likely. 
To provide evidence that the putative IFNλR1 and IL-10R2 constitute a functional chicken 
IFNλR complex, the expression of each chain was knocked down using siRNA. This 
demonstrated that both chains were needed for IFNλ-mediated STAT activation and ISG 
upregulation. Treatment with Ruxolitinib, a selective JAK1 inhibitor, also blocked IFNλ 
mediated responses. This collectively demonstrates an IFNλR1/IL-10R2-JAK-STAT-ISG 
pathway in chickens. Confirming the functionality of this central signaling cascade also opens 
up possibilities to repurpose drugs for pro-viral treatment. Ruxolitinib, which has FDA 
approval for used in myelofibrosis 329 treatment in humans, could be used to inhibit 
interferon signaling and enhance viral amplification for increasing yield for vaccine 
production 330,331 and sensitivity for diagnostic applications 249. 
The use of embryonated eggs for amplification of viruses  and the virus-host interaction has 
been characterized extensively in the past 60 years 332-346 but little to no work on the 
characterization of the egg immune system has been done since the discovery of IFNs in 
chicken egg 347. To gain insight into the developing immune response and potential factors 
inhibiting or failing to inhibit viral growth, chicken eggs were infected with Influenza A 
according to the same protocols used by the vaccine production industry and diagnostic 
laboratories348. The results suggest that IFNα is inhibited by the virus, which can be 
explained by the agonistic effect of the NS1 protein in H1N1 that is well documented 349. 
However, though IFN expression is repressed or delayed, ISGs are expressed at high levels in 
a tissue dependent fashion. The inoculation of the virus into the allantoic fluid 348 brings the 
virus into close contact with the inner layer the Chorio-allantoic membrane and the outer 
layer of embryonic tissue. By 24 h the virus replicates to very high levels in the CAM and by 
48 h the virus has spread to every tissue. This data shows that even in the absence of IFNα 
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the ISGs respond by 24 h to viral invasion, but this is not sufficient to control viral replication 
as by 48 h the virus has spread to every tissue of the embryo including the brain. This work 
gives insights into the localisation of viral replication as well as the mounting innate immune 
response, but more work needs to be done to dissect the various virus sensing and immune 
response inducing pathways in the developing chicken embryo. The data collected here 
suggests that the IFN system is well developed although unable to deal with a substantial 
viral infection in an appropriate manner.  
Limited knowledge around the effectors of the IFN-mediated antiviral response, the ISGs, 
hinders he progress in avian immunology. Compared to mammals the avian ISGs are very 
poorly characterized, with few genes analyzed. The first human ISG cloned was the 
interferon-induced proteins with Tetratricopeptide repeats (IFITs) 1 350. Considerable 
research has been performed on IFIT family members identifying a key role in anti-viral host 
defense by inhibiting virus replication through binding and regulating the functions of 
cellular and viral proteins and RNAs 351. The IFIT family consists of four members in human 
and three in mouse. All identified IFITs have multiple copies of Tetratricopeptide repeats 
(TRPs), their distinct tertiary structures enable them to bind different partners and affect 
host-virus interactions differently. Human IFIT1 and IFIT2 are thought interfere with the viral 
RNA translation by binding to the EIF3 352. Viral pppRNA is also recognized by IFIT1 which 
leads to sequestering by an IFIT1, IFIT2 and IFIT3 complex, although only IFIT1 is directly able 
to interact with ppp RNA. IFIT5 has been shown to also interact with ppp RNA but not with 
IFIT2 or IFIT3, indicating a non-redundant role in antiviral defense 227,353. 
A chicken IFIT homolog has been mentioned in several publications 231,284,300,301, but no in 
depth characterization of the gene has been performed. A single potential chicken IFIT gene 
candidate was identified, amplified by RT-PCR and sequenced. The encoded chicken IFIT 
protein showed greatest homology to the human IFIT5 and was thus named chicken IFIT5. 
The chicken IFIT5 was most closely related to other bird IFITs and possessed nine TRP 
domains are distributed over its length similar to other bird and human IFITs. The crystal 
structure of the human IFIT5 was recently solved with extensive mutation studies identifying 
residues critical for function 228. The chicken IFIT5 sequence showed conservation of 12 out 
of 16 residues identified as important for substrate binding specificity. Collectively, this 
points towards a functionally conserved IFIT gene in chickens. 
The expression of chicken IFIT5 was analyzed in response to different immune stimuli, 
including infection in vivo and in ovo. IFIT5 was highly induced in chicken cells after 
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treatment with PIC and LPS, while PIC triggered a significant increase in expression after 3 h 
with relatively stable expression up until 48 h. In contrast, LPS stimulation induced a peak 
expression after 6 h followed by a rapid decline. The IFIT5 gene was also induced in response 
to chIFNs like IFNα and IFNλ with similar kinetics to other ISGs observed, although induction 
by IFNα reached significant levels after 1.5 h and stayed significantly induced until 24 h. 
Following viral infection IFIT5 was highly induced in the lung and spleen of chickens infected 
with H5N6 HPAI and in the chorio-allantoic membrane and the muscle of infected 
embryonated eggs. This collectively suggests that chicken IFIT5 represents a bone fide ISG, 
with applicability to studies on chicken innate immune system and contribute to the 
understanding of HPAI pathogenesis in chickens. 
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11 Appendix 
Table 2 Accession Numbers of interferon sequences 
Accession Number Sign Species type 
NP990758 a chicken interferon alpha   
AAX83679.1 b chicken interferon beta   
AAU10091.1 g chicken interferon gamma   
ABU82742 l chicken interferon lambda   
ADU04501.1 o chicken interferon omega   
AAC41702 b human interferon beta   
AAI00873 e human interferon epsilon   
CAA41626 o human interferon omega   
CAA44325 g human interferon gamma   
CAA72532 a2 human interferon alpha 2 
EAW56869 l3 human interferon lambda 3 
EAW56870 l2 human interferon lambda 2 
EAW56871 l1 human interferon lambda 1 
EAW58609 a1 human interferon alpha 1 
EAW58610 a8 human interferon alpha 8 
EAW58612 a13 human interferon alpha 13 
EAW58613 a6 human interferon alpha 6 
EAW58615 a5 human interferon alpha 5 
EAW58616 a14 human interferon alpha 14 
EAW58617 a17 human interferon alpha 17 
EAW58618 a16 human interferon alpha 16 
EAW58619 a10 human interferon alpha 10 
EAW58620 a7 human interferon alpha 7 
EAW58621 a4 human interferon alpha 4 
EAW58623 a21 human interferon alpha 21 
EAW58563.1 k human interferon kappa   
NP482513660 l4 human interferon lambda 4 
AAA37888 a7 mouse interferon alpha 7 
AAA37891 b mouse interferon beta   
AAH99376 k mouse interferon kappa   
AAI04353 a12 mouse interferon alpha 12 
AAI04378 e mouse interferon epsilon   
AAI16873 a11 mouse interferon alpha 11 
AAI19352 a4 mouse interferon alpha 4 
AAI20725 a13 mouse interferon alpha 13 
AAI20912 a5 mouse interferon alpha 5 
AAI25322 a14 mouse interferon alpha 14 
AAX58714 l2 mouse interferon lambda   
AAX58715 l3 mouse interferon lambda   
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ACR22510 g mouse interferon gamma   
EDL30963 z mouse interferon zeta   
 
Table 3 Accession numbers of IFNλR1 sequences 
Accession 
Number   Species type 
XP011227661.1 Predicted  Ailuropoda melanoleuca 
 
Interferon 
lambd
a 
recepto
r 1 
KYO25772.1    Alligator mississippiensis 
 
Interferon 
lambd
a 
recepto
r 1 
XP006019447.1 Predicted  Alligator sinensis 
 
Interferon 
lambd
a 
recepto
r 1 
AHY86485.1    Anolis carolinensis 
 
Interferon 
lambd
a 
recepto
r 1 
AJD08473.1    Anser cygnoides 
 
Interferon 
lambd
a 
recepto
r 1 
XP012295126.1 Predicted  Aotus nancymaae 
 
Interferon 
lambd
a 
recepto
r 1 
XP009866512.1 Predicted  Apaloderma vittatum 
 
Interferon 
lambd
a 
recepto
r 1 
XP009274512.1 Predicted  Aptenodytes forsteri 
 
Interferon 
lambd
a 
recepto
r 1 
XP011582322.1 Predicted  Aquila chrysaetos canadensis 
 
Interferon 
lambd
a 
recepto
r 1 
XP007175194.1 Predicted 
 Balaenoptera acutorostrata 
scammoni 
 
Interferon 
lambd
a 
recepto
r 1 
XP010299251.1 Predicted  Balearica regulorum gibbericeps 
 
Interferon 
lambd
a 
recepto
r 1 
XP010828357.1 Predicted  Bison bison bison 
 
Interferon 
lambd
a 
recepto
r 1 
XP010132822.1 Predicted  Buceros rhinoceros silvestris 
 
Interferon 
lambd
a 
recepto
r 1 
XP014804126.1 Predicted  Calidris pugnax 
 
Interferon 
lambd
a 
recepto
r 1 
XP008998890.1 Predicted  Callithrix jacchus 
 
Interferon 
lambd
a 
recepto
r 1 
XP010955647.1 Predicted  Camelus bactrianus 
 
Interferon 
lambd
a 
recepto
r 1 
XP010988103.1 Predicted  Camelus dromedarius 
 
Interferon 
lambd
a 
recepto
r 1 
XP014423818.1 Predicted  Camelus ferus 
 
Interferon 
lambd
a 
recepto
r 1 
XP013829748.1 Predicted  Capra hircus 
 
Interferon 
lambd
a 
recepto
r 1 
XP010170252.1 Predicted  Caprimulgus carolinensis 
 
Interferon 
lambd
a 
recepto
r 1 
XP009707716.1 Predicted  Cariama cristata 
 
Interferon 
lambd
a 
recepto
r 1 
XP013009632.1 Predicted  Cavia porcellus 
 
Interferon 
lambd
a 
recepto
r 1 
XP004425789.1 Predicted  Ceratotherium simum simum 
 
Interferon 
lambd
a 
recepto
r 1 
XP009998894.1 Predicted  Chaetura pelagica 
 
Interferon 
lambd
a 
recepto
r 1 
XP009880511.1 Predicted  Charadrius vociferus 
 
Interferon 
lambd
a 
recepto
r 1 
XP007068110.1 Predicted  Chelonia mydas 
 
Interferon 
lambd
a 
recepto
r 1 
XP010128944.1 Predicted  Chlamydotis macqueenii 
 
Interferon 
lambd
a 
recepto
r 1 
XP005302269.1 Predicted  Chrysemys picta bellii 
 
Interferon 
lambd
a 
recepto
r 1 
XP010199749.1 Predicted  Colius striatus 
 
Interferon 
lambd
a 
recepto
r 1 
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XP005513512.1 Predicted  Columba livia 
 
Interferon 
lambd
a 
recepto
r 1 
XP004679439.1 Predicted  Condylura cristata 
 
Interferon 
lambd
a 
recepto
r 1 
XP008633390.1 Predicted  Corvus brachyrhynchos 
 
Interferon 
lambd
a 
recepto
r 1 
XP010406501.1 Predicted  Corvus cornix cornix 
 
Interferon 
lambd
a 
recepto
r 1 
XP007617245.1 Predicted  Cricetulus griseus 
 
Interferon 
lambd
a 
recepto
r 1 
XP007643617.1 Predicted  Cricetulus griseus 
 
Interferon 
lambd
a 
recepto
r 1 
XP009560095.1 Predicted  Cuculus canorus 
 
Interferon 
lambd
a 
recepto
r 1 
XP004465448.1 Predicted  Dasypus novemcinctus 
 
Interferon 
lambd
a 
recepto
r 1 
XP012887869.1 Predicted  Dipodomys ordii 
 
Interferon 
lambd
a 
recepto
r 1 
XP004705411.1 Predicted  Echinops telfairi 
 
Interferon 
lambd
a 
recepto
r 1 
XP009646796.1 Predicted  Egretta garzetta 
 
Interferon 
lambd
a 
recepto
r 1 
XP006883717.1 Predicted  Elephantulus edwardii 
 
Interferon 
lambd
a 
recepto
r 1 
XP008146305.1 Predicted  Eptesicus fuscus 
 
Interferon 
lambd
a 
recepto
r 1 
XP007522647.1 Predicted  Erinaceus europaeus 
 
Interferon 
lambd
a 
recepto
r 1 
XP010904278.1 Predicted  Esox lucius 
 
Interferon 
lambd
a 
recepto
r 1 
XP010154970.1 Predicted  Eurypyga helias 
 
Interferon 
lambd
a 
recepto
r 1 
XP005433108.1 Predicted  Falco cherrug 
 
Interferon 
lambd
a 
recepto
r 1 
XP005234192.1 Predicted  Falco peregrinus 
 
Interferon 
lambd
a 
recepto
r 1 
XP003989777.1 Predicted  Felis catus 
 
Interferon 
lambd
a 
recepto
r 1 
XP016152229.1 Predicted  Ficedula albicollis 
 
Interferon 
lambd
a 
recepto
r 1 
XP005058494.1 Predicted  Ficedula albicollis 
 
Interferon 
lambd
a 
recepto
r 1 
XP010624247.1 Predicted  Fukomys damarensis 
 
Interferon 
lambd
a 
recepto
r 1 
XP009578178.1 Predicted  Fulmarus glacialis 
 
Interferon 
lambd
a 
recepto
r 1 
AHF20241.1    Gallus gallus 
 
Interferon 
lambd
a 
recepto
r 1 
XP009805197.1 Predicted  Gavia stellata 
 
Interferon 
lambd
a 
recepto
r 1 
XP015261062.1 Predicted  Gekko japonicus 
 
Interferon 
lambd
a 
recepto
r 1 
XP005427215.2 Predicted  Geospiza fortis 
 
Interferon 
lambd
a 
recepto
r 1 
XP009917474.1 Predicted  Haliaeetus albicilla 
 
Interferon 
lambd
a 
recepto
r 1 
XP010574400.1 Predicted  Haliaeetus leucocephalus 
 
Interferon 
lambd
a 
recepto
r 1 
XP012929689.1 Predicted  Heterocephalus glaber 
 
Interferon 
lambd
a 
recepto
r 1 
AAI40873.1    Homo sapiens 
 
Interferon 
lambd
a 
recepto
r 1 
XP005318127.1 Predicted  Ictidomys tridecemlineatus 
 
Interferon 
lambd
a 
recepto
r 1 
XP012803978.1 Predicted  Jaculus jaculus 
 
Interferon 
lambd
a 
recepto
r 1 
XP009951551.1 Predicted  Leptosomus discolor 
 
Interferon 
lambd
a 
recepto
r 1 
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XP010593387.1 Predicted  Loxodonta africana 
 
Interferon 
lambd
a 
recepto
r 1 
XP014986729.1 Predicted  Macaca mulatta 
 
Interferon 
lambd
a 
recepto
r 1 
XP011761158.1 Predicted  Macaca nemestrina 
 
Interferon 
lambd
a 
recepto
r 1 
XP008918805.1 Predicted  Manacus vitellinus 
 
Interferon 
lambd
a 
recepto
r 1 
XP011833300.1 Predicted  Mandrillus leucophaeus 
 
Interferon 
lambd
a 
recepto
r 1 
XP010721813.1 Predicted  Meleagris gallopavo 
 
Interferon 
lambd
a 
recepto
r 1 
XP012986518.1 Predicted  Melopsittacus undulatus 
 
Interferon 
lambd
a 
recepto
r 1 
XP008933896.1 Predicted  Merops nubicus 
 
Interferon 
lambd
a 
recepto
r 1 
XP012975582.1 Predicted  Mesocricetus auratus 
 
Interferon 
lambd
a 
recepto
r 1 
XP012605910.1 Predicted  Microcebus murinus 
 
Interferon 
lambd
a 
recepto
r 1 
XP005353444.1 Predicted  Microtus ochrogaster 
 
Interferon 
lambd
a 
recepto
r 1 
XP001365104.2 Predicted  Monodelphis domestica 
 
Interferon 
lambd
a 
recepto
r 1 
XP005875259.2 Predicted  Myotis brandtii 
 
Interferon 
lambd
a 
recepto
r 1 
XP015412682.1 Predicted  Myotis davidii 
 
Interferon 
lambd
a 
recepto
r 1 
XP010021868.1 Predicted  Nestor notabilis 
 
Interferon 
lambd
a 
recepto
r 1 
XP009469068.1 Predicted  Nipponia nippon 
 
Interferon 
lambd
a 
recepto
r 1 
XP004592432.1 Predicted  Ochotona princeps 
 
Interferon 
lambd
a 
recepto
r 1 
XP004637786.1 Predicted  Octodon degus 
 
Interferon 
lambd
a 
recepto
r 1 
XP012415878.1 Predicted  Odobenus rosmarus divergens 
 
Interferon 
lambd
a 
recepto
r 1 
XP002716066.1 Predicted  Oryctolagus cuniculus 
 
Interferon 
lambd
a 
recepto
r 1 
XP015393611.1 Predicted  Panthera tigris altaica 
 
Interferon 
lambd
a 
recepto
r 1 
XP005954133.1 Predicted  Pantholops hodgsonii 
 
Interferon 
lambd
a 
recepto
r 1 
XP003891375.2 Predicted  Papio anubis 
 
Interferon 
lambd
a 
recepto
r 1 
XP015504532.1 Predicted  Parus major 
 
Interferon 
lambd
a 
recepto
r 1 
XP009486303.1 Predicted  Pelecanus crispus 
 
Interferon 
lambd
a 
recepto
r 1 
XP010281772.1 Predicted  Phaethon lepturus 
 
Interferon 
lambd
a 
recepto
r 1 
XP009513439.1 Predicted  Phalacrocorax carbo 
 
Interferon 
lambd
a 
recepto
r 1 
XP007121168.1 Predicted  Physeter catodon 
 
Interferon 
lambd
a 
recepto
r 1 
XP009906845.1 Predicted  Picoides pubescens 
 
Interferon 
lambd
a 
recepto
r 1 
XP014113903.1 Predicted  Pseudopodoces humilis 
 
Interferon 
lambd
a 
recepto
r 1 
XP010080597.1 Predicted  Pterocles gutturalis 
 
Interferon 
lambd
a 
recepto
r 1 
AEQ38017.1    Pteropus alecto 
 
Interferon 
lambd
a 
recepto
r 1 
XP009330413.1 Predicted  Pygoscelis adeliae 
 
Interferon 
lambd
a 
recepto
r 1 
XP012400962.1 Predicted  Sarcophilus harrisii 
 
Interferon 
lambd
a 
recepto
r 1 
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XP009096915.1 Predicted  Serinus canaria 
 
Interferon 
lambd
a 
recepto
r 1 
XP016309571.1 Predicted  Sinocyclocheilus anshuiensis 
 
Interferon 
lambd
a 
recepto
r 1 
XP012787040.1 Predicted  Sorex araneus 
 
Interferon 
lambd
a 
recepto
r 1 
XP009666548.1 Predicted  Struthio camelus australis 
 
Interferon 
lambd
a 
recepto
r 1 
XP014741053.1 Predicted  Sturnus vulgaris 
 
Interferon 
lambd
a 
recepto
r 1 
XP004174443.1 Predicted  Taeniopygia guttata 
 
Interferon 
lambd
a 
recepto
r 1 
XP008060367.1 Predicted  Tarsius syrichta 
 
Interferon 
lambd
a 
recepto
r 1 
XP009987356.1 Predicted  Tauraco erythrolophus 
 
Interferon 
lambd
a 
recepto
r 1 
XP010223088.1 Predicted  Tinamus guttatus 
 
Interferon 
lambd
a 
recepto
r 1 
XP014447446.1 Predicted  Tupaia chinensis 
 
Interferon 
lambd
a 
recepto
r 1 
XP009975065.1 Predicted  Tyto alba 
 
Interferon 
lambd
a 
recepto
r 1 
XP015093173.1 Predicted  Vicugna pacos 
 
Interferon 
lambd
a 
recepto
r 1 
ACV32138.1 
 transcript variant 
1  Xenopus tropicalis 
 
Interferon 
lambd
a 
recepto
r 1 
ACV32139.1 
 transcript variant 
2  Xenopus tropicalis 
 
Interferon 
lambd
a 
recepto
r 1 
ACV32140.1 
 transcript variant 
3   Xenopus tropicalis 
 
Interferon 
lambd
a 
recepto
r 1 
XP005494786.2 Predicted  Zonotrichia albicollis 
 
Interferon 
lambd
a 
recepto
r 1 
NP001184131.1 Precurser Danio rerio 
 
Interferon 
lambd
a 
recepto
r 1 
 
Table 4 Accession Numbers of IFNAR1 sequences 
Accession Number   Species type 
XP014918068.1 Predicted  Acinonyx jubatus  Interferon alpha/beta receptor alpha 
XP002919632.2 Predicted  Ailuropoda melanoleuca  Interferon alpha/beta receptor alpha 
KYO22780.1    Alligator mississippiensis  Interferon alpha/beta receptor alpha 
XP008120201.1 Predicted  Anolis carolinensis  Interferon alpha/beta receptor alpha 
AJD38996.1    Anser cygnoides  Interferon alpha/beta receptor alpha 
XP012302648.1 Predicted  Aotus nancymaae  Interferon alpha/beta receptor alpha 
XP009868282.1 Predicted  Apaloderma vittatum  Interferon alpha/beta receptor alpha 
XP009281347.1 Predicted  Aptenodytes forsteri  Interferon alpha/beta receptor alpha 
XP013810825.1 Predicted  Apteryx australis mantelli  Interferon alpha/beta receptor alpha 
XP010860591.1 Predicted  Bison bison bison  Interferon alpha/beta receptor alpha 
XP005893409.1 Predicted  Bos mutus  Interferon alpha/beta receptor alpha 
XP006048305.1 Predicted  Bubalus bubalis  Interferon alpha/beta receptor alpha 
XP010143146.1 Predicted  Buceros rhinoceros silvestris  Interferon alpha/beta receptor alpha 
XP014793775.1 Predicted  Calidris pugnax  Interferon alpha/beta receptor alpha 
XP002761441.1 Predicted  Callithrix jacchus  Interferon alpha/beta receptor alpha 
XP008494921.1 Predicted  Calypte anna  Interferon alpha/beta receptor alpha 
XP010954868.1 Predicted  Camelus bactrianus  Interferon alpha/beta receptor alpha 
XP013819137.1 Predicted  Capra hircus  Interferon alpha/beta receptor alpha 
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XP010166276.1 Predicted  Caprimulgus carolinensis  Interferon alpha/beta receptor alpha 
XP008065125.1 Predicted  Carlito syrichta  Interferon alpha/beta receptor alpha 
XP010002987.1 Predicted  Chaetura pelagica  Interferon alpha/beta receptor alpha 
XP009893221.1 Predicted  Charadrius vociferus  Interferon alpha/beta receptor alpha 
XP006862663.1 Predicted  Chrysochloris asiatica  Interferon alpha/beta receptor alpha 
XP011815546.1 Predicted  Colobus angolensis palliatus  Interferon alpha/beta receptor alpha 
XP013225464.1 Predicted  Columba livia  Interferon alpha/beta receptor alpha 
XP008638917.1 Predicted  Corvus brachyrhynchos  Interferon alpha/beta receptor alpha 
XP007619344.2 Predicted  Cricetulus griseus  Interferon alpha/beta receptor alpha 
XP009565463.1 Predicted  Cuculus canorus  Interferon alpha/beta receptor alpha 
XP012373471.1 Predicted  Dasypus novemcinctus  Interferon alpha/beta receptor alpha 
XP012882888.1 Predicted  Dipodomys ordii  Interferon alpha/beta receptor alpha 
XP004711386.1 Predicted  Echinops telfairi  Interferon alpha/beta receptor alpha 
XP009639194.1 Predicted  Egretta garzetta  Interferon alpha/beta receptor alpha 
XP006886853.1 Predicted  Elephantulus edwardii  Interferon alpha/beta receptor alpha 
XP008144026.1 Predicted  Eptesicus fuscus  Interferon alpha/beta receptor alpha 
XP014699230.1 Predicted  Equus asinus  Interferon alpha/beta receptor alpha 
XP001494689.3 Predicted  Equus caballus  Interferon alpha/beta receptor alpha 
XP008515476.1 Predicted  Equus przewalskii  Interferon alpha/beta receptor alpha 
XP007519772.1 Predicted  Erinaceus europaeus  Interferon alpha/beta receptor alpha 
XP010157283.1 Predicted  Eurypyga helias  Interferon alpha/beta receptor alpha 
XP005438665.1 Predicted  Falco cherrug  Interferon alpha/beta receptor alpha 
XP005234444.1 Predicted  Falco peregrinus  Interferon alpha/beta receptor alpha 
XP011284053.1 Predicted  Felis catus  Interferon alpha/beta receptor alpha 
XP010607017.1 Predicted  Fukomys damarensis  Interferon alpha/beta receptor alpha 
AAD13669.1    Gallus gallus  Interferon alpha/beta receptor alpha 
XP014165295.1 Predicted  Geospiza fortis  Interferon alpha/beta receptor alpha 
XP004062764.1 Predicted  Gorilla gorilla gorilla  Interferon alpha/beta receptor alpha 
XP010583626.1 Predicted  Haliaeetus leucocephalus  Interferon alpha/beta receptor alpha 
XP004842365.1 Predicted  Heterocephalus glaber  Interferon alpha/beta receptor alpha 
AAT49100.1    Homo sapiens  Interferon alpha/beta receptor alpha 
XP012803362.1 Predicted  Jaculus jaculus  Interferon alpha/beta receptor alpha 
XP006012924.1 Predicted  Latimeria chalumnae  Interferon alpha/beta receptor alpha 
XP006749269.1 Predicted  Leptonychotes weddellii  Interferon alpha/beta receptor alpha 
XP009949621.1 Predicted  Leptosomus discolor  Interferon alpha/beta receptor alpha 
XP007447468.1 Predicted  Lipotes vexillifer  Interferon alpha/beta receptor alpha 
XP011724842.1 Predicted  Macaca nemestrina  Interferon alpha/beta receptor alpha 
XP008924472.1 Predicted  Manacus vitellinus  Interferon alpha/beta receptor alpha 
XP011854503.1 Predicted  Mandrillus leucophaeus  Interferon alpha/beta receptor alpha 
XP015334189.1 Predicted  Marmota marmota marmota  Interferon alpha/beta receptor alpha 
XP010721604.1 Predicted  Meleagris gallopavo  Interferon alpha/beta receptor alpha 
XP012971606.1 Predicted  Mesocricetus auratus  Interferon alpha/beta receptor alpha 
XP012602506.1 Predicted  Microcebus murinus  Interferon alpha/beta receptor alpha 
XP016069000.1 Predicted  Miniopterus natalensis  Interferon alpha/beta receptor alpha 
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AAH52217.1    Mus musculus  Interferon alpha/beta receptor alpha 
XP004757568.1 Predicted  Mustela putorius furo  Interferon alpha/beta receptor alpha 
XP014390685.1 Predicted  Myotis brandtii  Interferon alpha/beta receptor alpha 
XP015415723.1 Predicted  Myotis davidii  Interferon alpha/beta receptor alpha 
XP010017322.1 Predicted  Nestor notabilis  Interferon alpha/beta receptor alpha 
XP009471830.1 Predicted  Nipponia nippon  Interferon alpha/beta receptor alpha 
XP012373317.1 Predicted  Octodon degus  Interferon alpha/beta receptor alpha 
XP004406365.1 Predicted  Odobenus rosmarus divergens  Interferon alpha/beta receptor alpha 
ETE57640.1    Ophiophagus hannah  Interferon alpha/beta receptor alpha 
XP009931683.1 Predicted  Opisthocomus hoazin  Interferon alpha/beta receptor alpha 
XP004264572.1 Predicted  Orcinus orca  Interferon alpha/beta receptor alpha 
XP007667937.1 Predicted  Ornithorhynchus anatinus  Interferon alpha/beta receptor alpha 
XP007939497.1 Predicted  Orycteropus afer afer  Interferon alpha/beta receptor alpha 
XP007090486.1 Predicted  Panthera tigris altaica  Interferon alpha/beta receptor alpha 
NP001162254.1    Papio anubis  Interferon alpha/beta receptor alpha 
XP006126098.1 Predicted  Pelodiscus sinensis  Interferon alpha/beta receptor alpha 
XP007115989.1 Predicted  Physeter catodon  Interferon alpha/beta receptor alpha 
XP009905697.1 Predicted  Picoides pubescens  Interferon alpha/beta receptor alpha 
XP002830697.2 Predicted  Pongo abelii  Interferon alpha/beta receptor alpha 
XP012512783.1 Predicted  Propithecus coquereli  Interferon alpha/beta receptor alpha 
XP015675028.1 Predicted  Protobothrops mucrosquamatus  Interferon alpha/beta receptor alpha 
XP006921038.1 Predicted  Pteropus alecto  Interferon alpha/beta receptor alpha 
XP011363988.1 Predicted  Pteropus vampyrus  Interferon alpha/beta receptor alpha 
XP009326292.1 Predicted  Pygoscelis adeliae  Interferon alpha/beta receptor alpha 
XP016017904.1 Predicted  Rousettus aegyptiacus  Interferon alpha/beta receptor alpha 
XP003927702.1 Predicted  Saimiri boliviensis boliviensis  Interferon alpha/beta receptor alpha 
XP009098361.1 Predicted  Serinus canaria  Interferon alpha/beta receptor alpha 
XP004620396.1 Predicted  Sorex araneus  Interferon alpha/beta receptor alpha 
XP009665899.1 Predicted  Struthio camelus australis  Interferon alpha/beta receptor alpha 
XP014745867.1 Predicted  Sturnus vulgaris  Interferon alpha/beta receptor alpha 
BAD06315.1    Sus scrofa  Interferon alpha/beta receptor alpha 
JAG69468.1    Sus scrofa domesticus  Interferon alpha/beta receptor alpha 
XP012424842.1 Predicted  Taeniopygia guttata  Interferon alpha/beta receptor alpha 
XP010211787.1 Predicted  Tinamus guttatus  Interferon alpha/beta receptor alpha 
XP006153941.1 Predicted  Tupaia chinensis  Interferon alpha/beta receptor alpha 
XP004317420.1 Predicted  Tursiops truncatus  Interferon alpha/beta receptor alpha 
 
Table 5 Accession Numbers of IL10R2 sequences 
Accession Number   Species type 
XP6032721 PREDICTED: Alligator sinensis.   Interleukin 10 receptor beta 
AGC95877.1   Anas platyrhynchos   interleukin 10 receptor beta 
XP8120200 PREDICTED: Anolis carolinensis.   interleukin 10 receptor beta 
XP013048351.1 PREDICTED: Anser cygnoides domesticus   Interleukin 10 receptor beta 
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XP009865443.1 PREDICTED: Apaloderma vittatum   interleukin 10 receptor beta 
XP9865443 PREDICTED: Apalodermavittatum.   interleukin 10 receptor beta 
XP009281346.1 PREDICTED: Aptenodytes forsteri   interleukin 10 receptor beta 
XP9281346 PREDICTED: Aptenodytesforsteri.   Interleukin 10 receptor beta 
XP011592119.1 PREDICTED: Aquila chrysaetos canadensis   interleukin 10 receptor beta 
XP7183767 PREDICTED: Balaenopteraacutorostrata scammoni.   Interleukin 10 receptor beta 
XP5893408 PREDICTED: Bos mutus.   interleukin 10 receptor beta 
AAI23562   Bos taurus.   Interleukin 10 receptor beta 
XP6048306 PREDICTED: Bubalusbubalis.   Interleukin 10 receptor beta 
XP014793464.1 PREDICTED: Calidris pugnax   interleukin 10 receptor beta 
XP535581 PREDICTED: Canis lupusfamiliaris.   interleukin 10 receptor beta 
XP5674740 PREDICTED: Capra hircus.   interleukin 10 receptor beta 
XP3467317 PREDICTED: Cavia porcellus.   interleukin 10 receptor beta 
XP4429624 PREDICTED: Ceratotheriumsimum simum.   Interleukin 10 receptor beta 
XP010002989.1 PREDICTED: Chaetura pelagica   interleukin 10 receptor beta 
XP10002989 PREDICTED: Chaeturapelagica.   interleukin 10 receptor beta 
XP009893222.1 PREDICTED: Charadrius vociferus   Interleukin 10 receptor beta 
XP9893222 PREDICTED: Charadriusvociferus.   interleukin 10 receptor beta 
XP007063661.1 PREDICTED: Chelonia mydas   Interleukin 10 receptor beta 
XP7063661 PREDICTED: Chelonia mydas.   interleukin 10 receptor beta 
XP7962829 PREDICTED: Chlorocebussabaeus.   interleukin 10 receptor beta 
XP6862662 PREDICTED: Chrysochlorisasiatica.   interleukin 10 receptor beta 
XP005511441.1 PREDICTED: Columba livia   interleukin 10 receptor beta 
XP5511441 PREDICTED: Columba livia.   interleukin 10 receptor beta 
XP4675580 PREDICTED: Condyluracristata.   interleukin 10 receptor beta 
XP008638918.1 PREDICTED: Corvus brachyrhynchos   Interleukin 10 receptor beta 
XP8638918 PREDICTED: Corvus brachyrhynchos.   interleukin 10 receptor beta 
XP009565422.1 PREDICTED: Cuculus canorus   interleukin 10 receptor beta 
XP9565422 PREDICTED: Cuculus canorus.   interleukin 10 receptor beta 
XP4474575 PREDICTED: Dasypusnovemcinctus.   interleukin 10 receptor beta 
XP4711385 PREDICTED: Echinopstelfairi.   interleukin 10 receptor beta 
XP009639193.1 PREDICTED: Egretta garzetta   interleukin 10 receptor beta 
XP9639193 PREDICTED: Egretta garzetta.   interleukin 10 receptor beta 
XP6886855 PREDICTED: Elephantulusedwardii.   interleukin 10 receptor beta 
XP8144027 PREDICTED: Eptesicus fuscus.   interleukin 10 receptor beta 
XP7519798 PREDICTED: Erinaceuseuropaeus.   interleukin 10 receptor beta 
XP014134992.1 PREDICTED: Falco cherrug   interleukin 10 receptor beta 
XP5438666 PREDICTED: Falco cherrug.   interleukin 10 receptor beta 
XP013152260.1 PREDICTED: Falco peregrinus   interleukin 10 receptor beta 
XP5234443 PREDICTED: Falco peregrinus.   interleukin 10 receptor beta 
XP8565345 PREDICTED: Galeopterus variegatus.   interleukin 10 receptor beta 
AAD13678   Gallus gallus.   interleukin 10 receptor beta 
XP5427850 PREDICTED: Geospiza fortis.   interleukin 10 receptor beta 
XP4062758 PREDICTED: gorilla gorilla.   interleukin 10 receptor beta 
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XP010583627.1 PREDICTED: Haliaeetus leucocephalus   interleukin 10 receptor beta 
AAH01903   Homo sapiens.   interleukin 10 receptor beta 
AHH37769.1   Ictalurus punctatus   interleukin 10 receptor beta 
XP5323582 PREDICTED: Ictidomystridecemlineatus.   Interleukin 10 receptor beta 
XP4654632 PREDICTED: Jaculus jaculus.   interleukin 10 receptor beta 
XP6749268 PREDICTED: Leptonychotesweddellii.   interleukin 10 receptor beta 
XP008924473.1 PREDICTED: Manacus vitellinus   interleukin 10 receptor beta 
XP8924473 PREDICTED: Manacus vitellinus.   interleukin 10 receptor beta 
XP010721250.1 PREDICTED: Meleagris gallopavo   interleukin 10 receptor beta 
XP5151846 PREDICTED: Melopsittacusundulatus.   interleukin 10 receptor beta 
XP010182246.1 PREDICTED: Mesitornis unicolor   interleukin 10 receptor beta 
XP10182246 PREDICTED: Mesitornisunicolor.   Interleukin 10 receptor beta 
XP5345262 PREDICTED: Microtusochrogaster.   Interleukin 10 receptor beta 
XP7493332 PREDICTED: Monodelphisdomestica.   Interleukin 10 receptor beta 
AAI45792   Mus musculus.   Interleukin 10 receptor beta 
XP5860815 PREDICTED: Myotis brandtii.   interleukin 10 receptor beta 
XP6753184 PREDICTED: Myotis davidii.   interleukin 10 receptor beta 
XP010011567.1 PREDICTED: Nestor notabilis   interleukin 10 receptor beta 
XP10011567 PREDICTED: Nestor notabilis.   interleukin 10 receptor beta 
XP009471772.1 PREDICTED: Nipponia nippon   interleukin 10 receptor beta 
XP9471772 PREDICTED: Nipponia nippon.   Interleukin 10 receptor beta 
XP3263916 PREDICTED: Nomascusleucogenys.   interleukin 10 receptor beta 
XP4588675 PREDICTED: Ochotonaprinceps.   interleukin 10 receptor beta 
XP4645413 PREDICTED: Octodon degus.   interleukin 10 receptor beta 
XP4406336 PREDICTED: Odobenus rosmarusdivergens.   Interleukin 10 receptor beta 
XP009931682.1 PREDICTED: Opisthocomus hoazin   Interleukin 10 receptor beta 
XP9931682 PREDICTED: Opisthocomushoazin.   interleukin 10 receptor beta 
XP4264570 PREDICTED: Orcinus orca.   interleukin 10 receptor beta 
XP1514079 PREDICTED: Ornithorhynchusanatinus.   interleukin 10 receptor beta 
XP7939498 PREDICTED: Orycteropus aferafer.   interleukin 10 receptor beta 
XP3797149 PREDICTED: Otolemurgarnettii   interleukin 10 receptor beta 
JAA32934   Pan troglodytes   interleukin 10 receptor beta 
XP7090484 PREDICTED: Panthera tigrisaltaica.   interleukin 10 receptor beta 
XP5954316 PREDICTED: Pantholops hodgsonii.   interleukin 10 receptor beta 
XP006126099.1 PREDICTED: Pelodiscus sinensis   interleukin 10 receptor beta 
XP6126099 PREDICTED: Pelodiscus sinensis.   interleukin 10 receptor beta 
XP6983640 PREDICTED: Peromyscusmaniculatus bairdii.   interleukin 10 receptor beta 
XP010292505.1 PREDICTED: Phaethon lepturus   interleukin 10 receptor beta 
XP10292505 PREDICTED: Phaethonlepturus.   interleukin 10 receptor beta 
XP5526692 PREDICTED: Pseudopodoceshumilis.   interleukin 10 receptor beta 
AEQ38018   Pteropus alecto.   interleukin 10 receptor beta 
XP009326291.1 PREDICTED: Pygoscelis adeliae   interleukin 10 receptor beta 
XP3927704 PREDICTED: Saimiriboliviensis boliviensis.   interleukin 10 receptor beta 
XP009098360.1 PREDICTED: Serinus canaria   interleukin 10 receptor beta 
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XP9098360 PREDICTED: Serinus canaria.   interleukin 10 receptor beta 
XP4620397 PREDICTED: Sorex araneus.   interleukin 10 receptor beta 
XP009665944.1 PREDICTED: Struthio camelus australis   interleukin 10 receptor beta 
XP9665944 PREDICTED: Struthio camelusaustralis.   interleukin 10 receptor beta 
XP014745841.1 PREDICTED: Sturnus vulgaris   interleukin 10 receptor beta 
BAD06316   Sus scrofa.   interleukin 10 receptor beta 
XP012424838.1 PREDICTED: Taeniopygia guttata   Interleukin 10 receptor beta 
XP010211788.1 PREDICTED: Tinamus guttatus   interleukin 10 receptor beta 
XP10211788 PREDICTED: Tinamus guttatus.   Interleukin 10 receptor beta 
XP4317421 PREDICTED: Tursiopstruncatus.   interleukin 10 receptor beta 
XP009967534.1 PREDICTED: Tyto alba   interleukin 10 receptor beta 
XP9967534 PREDICTED: Tyto alba.   interleukin 10 receptor beta 
XP6216099 PREDICTED: Vicugna pacos.   interleukin 10 receptor beta 
NP1165294 precursor Xenopus (Silurana)tropicalis.   interleukin 10 receptor beta 
NP1087014 precursor Xenopus laevis.   interleukin 10 receptor beta 
 
Table 6 Accession Numbers of IFIT sequences 
Accession Number   Species type 
ENSAMEG00000020101    Ailuropoda melanoleuca  IFIT2   
ENSAMEG00000018958    Ailuropoda melanoleuca  IFIT5   
ENSAMEG00000020102  predicted Ailuropoda melanoleuca  IFIT 
ENSAMEG00000020103  predicted Ailuropoda melanoleuca  IFIT 
KF956064  Anas platyrhynchos  IFIT 
ENSACAG00000024133  predicted Anolis carolinensis  IFIT 
ENSACAG00000027620 predicted Anolis carolinensis  IFIT 
ENSBTAG00000007881    Bos taurus  IFIT1   
ENSBTAG00000034918    Bos taurus  IFIT2   
ENSBTAG00000009768    Bos taurus  IFIT3   
ENSBTAG00000017367    Bos taurus  IFIT5   
ENSCJAG00000005746    Callithrix jacchus  IFIT1   
ENSCJAG00000005737    Callithrix jacchus  IFIT2   
ENSCJAG00000005741    Callithrix jacchus  IFIT3   
ENSCJAG00000011216    Callithrix jacchus  IFIT5   
ENSCAFG00000009617    Canis familiaris  IFIT1   
ENSCAFG00000009612    Canis familiaris  IFIT2   
ENSCAFG00000031614    Canis familiaris  IFIT3   
ENSCAFG00000007151  predicted Canis familiaris  IFIT 
ENSCAFG00000031100  predicted Canis familiaris  IFIT 
ENSCPOG00000009345    Cavia porcellus  IFIT1B   
ENSCPOG00000008531    Cavia porcellus  IFIT5   
ENSCHOG00000005879    Choloepus hoffmanni  IFIT2   
ENSCHOG00000003530    Choloepus hoffmanni  IFIT3   
ENSCHOG00000004669    Choloepus hoffmanni  IFIT5   
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ENSCHOG00000004664  predicted Choloepus hoffmanni  IFIT 
ENSCHOG00000004668  predicted Choloepus hoffmanni  IFIT 
ENSDNOG00000044243    Dasypus novemcinctus  IFIT2   
ENSDNOG00000000986    Dasypus novemcinctus  IFIT3   
ENSDNOG00000008825    Dasypus novemcinctus  IFIT5   
ENSDNOG00000008816  predicted Dasypus novemcinctus  IFIT 
ENSDNOG00000045605  predicted Dasypus novemcinctus  IFIT 
ENSDORG00000003058  predicted Dipodomys ordii  IFIT 
ENSDORG00000012514  predicted Dipodomys ordii  IFIT 
ENSDORG00000012515  predicted Dipodomys ordii  IFIT 
ENSETEG00000014714    Echinops telfairi  IFIT5   
ENSECAG00000004433    Equus caballus  IFIT1   
ENSECAG00000010153    Equus caballus  IFIT4   
ENSECAG00000004349    Equus caballus  IFIT5   
ENSEEUG00000000242    Erinaceus europaeus  IFIT3   
ENSEEUG00000002041    Erinaceus europaeus  IFIT5   
ENSFCAG00000011708    Felis catus  IFIT2   
ENSFCAG00000018779    Felis catus  IFIT3   
ENSFCAG00000005933  predicted Felis catus  IFIT 
ENSFCAG00000007421  predicted Felis catus  IFIT 
ENSFCAG00000012538  predicted Felis catus  IFIT 
ENSFCAG00000031175  predicted Felis catus  IFIT 
ENSFALG00000007677  predicted Ficedula albicollis  IFIT 
ENSGGOG00000023234    Gorilla gorilla  IFIT1   
ENSGGOG00000023376    Gorilla gorilla  IFIT1B   
ENSGGOG00000010407    Gorilla gorilla  IFIT2   
ENSGGOG00000012012    Gorilla gorilla  IFIT3   
ENSGGOG00000003981    Gorilla gorilla  IFIT5   
ENSGGOG00000022599  predicted Gorilla gorilla  IFIT 
ENSG00000185745    Homo sapiens  IFIT1   
ENSG00000204010    Homo sapiens  IFIT1B   
ENSG00000119922    Homo sapiens  IFIT2   
ENSG00000119917    Homo sapiens  IFIT3   
ENSG00000152778    Homo sapiens  IFIT5   
ENSSTOG00000024733    Ictidomys tridecemlineatus  IFIT1   
ENSSTOG00000022564    Ictidomys tridecemlineatus  IFIT2   
ENSSTOG00000013100    Ictidomys tridecemlineatus  IFIT3   
ENSSTOG00000028876    Ictidomys tridecemlineatus  IFIT5   
ENSSTOG00000007101  predicted Ictidomys tridecemlineatus  IFIT 
ENSSTOG00000024810  predicted Ictidomys tridecemlineatus  IFIT 
ENSSTOG00000026318  predicted Ictidomys tridecemlineatus  IFIT 
ENSSTOG00000026437  predicted Ictidomys tridecemlineatus  IFIT 
ENSSTOG00000027912  predicted Ictidomys tridecemlineatus  IFIT 
ENSLACG00000004609  predicted Latimeria chalumnae  IFIT 
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ENSLACG00000004753  predicted Latimeria chalumnae  IFIT 
ENSLAFG00000008209    Loxodonta africana  IFIT3   
ENSLAFG00000011455    Loxodonta africana  IFIT5   
ENSLAFG00000008208  predicted Loxodonta africana  IFIT 
ENSLAFG00000028666  predicted Loxodonta africana  IFIT 
ENSMEUG00000002401    Macropus eugenii  IFIT5   
ENSMGAG00000015330  predicted Meleagris gallopavo  IFIT 
ENSMICG00000014624    Microcebus murinus  IFIT3   
ENSMICG00000016819    Microcebus murinus  IFIT5   
ENSMICG00000014633  predicted Microcebus murinus  IFIT 
ENSMICG00000014997  predicted Microcebus murinus  IFIT 
ENSMODG00000007358  predicted Monodelphis domestica  IFIT 
ENSMODG00000024881  predicted Monodelphis domestica  IFIT 
ENSMODG00000024882  predicted Monodelphis domestica  IFIT 
ENSMODG00000028143  predicted Monodelphis domestica  IFIT 
ENSMUSG00000034459    Mus musculus  IFIT1   
ENSMUSG00000045932    Mus musculus  IFIT2   
ENSMUSG00000074896    Mus musculus  IFIT3   
ENSMPUG00000006489    Mustela putorius furo  IFIT2   
ENSMPUG00000020198    Mustela putorius furo  IFIT3   
ENSMPUG00000017274    Mustela putorius furo  IFIT5   
ENSMPUG00000020197  predicted Mustela putorius furo  IFIT 
ENSMPUG00000006482  predicted Mustela putorius furo  IFIT 
ENSMLUG00000016645    Myotis lucifugus  IFIT2   
ENSMLUG00000016653    Myotis lucifugus  IFIT3   
ENSMLUG00000005766    Myotis lucifugus  IFIT5   
ENSMLUG00000016659  predicted Myotis lucifugus  IFIT 
ENSMLUG00000024075  predicted Myotis lucifugus  IFIT 
ENSNLEG00000012308    Nomascus leucogenys  IFIT1   
ENSNLEG00000018636    Nomascus leucogenys  IFIT1B   
ENSNLEG00000018635    Nomascus leucogenys  IFIT2   
ENSNLEG00000019258    Nomascus leucogenys  IFIT3   
ENSNLEG00000019104    Nomascus leucogenys  IFIT5   
ENSOPRG00000015105    Ochotona princeps  IFIT2   
ENSOPRG00000015110    Ochotona princeps  IFIT3   
ENSOPRG00000014668    Ochotona princeps  IFIT5   
ENSOPRG00000000056  predicted Ochotona princeps  IFIT 
ENSOPRG00000015788  predicted Ochotona princeps  IFIT 
ENSOPRG00000015791  predicted Ochotona princeps  IFIT 
ENSOANG00000005322  predicted Ornithorhynchus anatinus  IFIT 
ENSOANG00000007390  predicted Ornithorhynchus anatinus  IFIT 
ENSOANG00000010184  predicted Ornithorhynchus anatinus  IFIT 
ENSOCUG00000024939    Oryctolagus cuniculus  IFIT2   
ENSOCUG00000029154    Oryctolagus cuniculus  IFIT3   
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ENSOCUG00000024570    Oryctolagus cuniculus  IFIT5   
ENSOCUG00000004197  predicted Oryctolagus cuniculus  IFIT 
ENSOCUG00000005438  predicted Oryctolagus cuniculus  IFIT 
ENSOCUG00000005445  predicted Oryctolagus cuniculus  IFIT 
ENSORLG00000008314  predicted Oryzias latipes  IFIT 
ENSORLG00000013161  predicted Oryzias latipes  IFIT 
ENSORLG00000013238  predicted Oryzias latipes  IFIT 
ENSORLG00000013495  predicted Oryzias latipes  IFIT 
ENSORLG00000013503  predicted Oryzias latipes  IFIT 
ENSORLG00000019695  predicted Oryzias latipes  IFIT 
ENSORLG00000020438  predicted Oryzias latipes  IFIT 
ENSORLG00000020439  predicted Oryzias latipes  IFIT 
ENSOGAG00000031058    Otolemur garnettii  IFIT1   
ENSOGAG00000027677    Otolemur garnettii  IFIT2   
ENSOGAG00000002215    Otolemur garnettii  IFIT3   
ENSOGAG00000009660    Otolemur garnettii  IFIT5   
ENSOARG00000015177    Ovis aries  IFIT1   
ENSOARG00000015169    Ovis aries  IFIT2   
ENSOARG00000014800    Ovis aries  IFIT3   
ENSOARG00000014815    Ovis aries  IFIT5   
ENSPTRG00000029833    Pan troglodytes  IFIT1B   
ENSPTRG00000002733    Pan troglodytes  IFIT2   
ENSPTRG00000029834    Pan troglodytes  IFIT3   
ENSPTRG00000002736    Pan troglodytes  IFIT5   
ENSPANG00000021700    Papio anubis  IFIT1   
ENSPANG00000010650    Papio anubis  IFIT1B   
ENSPANG00000021698    Papio anubis  IFIT2   
ENSPANG00000021699    Papio anubis  IFIT3   
ENSPANG00000021702    Papio anubis  IFIT5   
ENSPSIG00000000678  predicted Pelodiscus sinensis  IFIT 
ENSPPYG00000002466    Pongo abelii  IFIT1   
ENSPPYG00000002465    Pongo abelii  IFIT1B   
ENSPPYG00000002463    Pongo abelii  IFIT2   
ENSPPYG00000002464    Pongo abelii  IFIT3   
ENSPPYG00000002467    Pongo abelii  IFIT5   
ENSPCAG00000014616    Procavia capensis  IFIT5   
ENSPVAG00000003647    Pteropus vampyrus  IFIT5   
ENSRNOG00000019050    Rattus norvegicus  IFIT1   
ENSRNOG00000036603    Rattus norvegicus  IFIT1lb   
ENSRNOG00000036604    Rattus norvegicus  IFIT2   
ENSRNOG00000022839    Rattus norvegicus  IFIT3   
ENSSHAG00000001370  predicted Sarcophilus harrisii  IFIT 
ENSSHAG00000002618  predicted Sarcophilus harrisii  IFIT 
ENSSHAG00000014976  predicted Sarcophilus harrisii  IFIT 
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ENSSARG00000001228    Sorex araneus  IFIT5   
ENSSSCG00000010453    Sus scrofa  IFIT1   
ENSSSCG00000010451    Sus scrofa  IFIT2   
ENSSSCG00000010452    Sus scrofa  IFIT3   
ENSSSCG00000010454    Sus scrofa  IFIT5   
ENSTGUG00000008354  predicted Taeniopygia guttata  IFIT 
ENSTSYG00000010287    Tarsius syrichta  IFIT1B   
ENSTSYG00000011715    Tarsius syrichta  IFIT5   
ENSTSYG00000019338  predicted Tarsius syrichta  IFIT 
ENSTSYG00000019354  predicted Tarsius syrichta  IFIT 
ENSTNIG00000002787    Tetraodon nigroviridis  IFIT2   
ENSTBEG00000002666    Tupaia belangeri  IFIT3   
ENSTBEG00000002771  predicted Tupaia belangeri  IFIT 
ENSTBEG00000003552  predicted Tupaia belangeri  IFIT 
ENSTTRG00000015419    Tursiops truncatus  IFIT1   
ENSTTRG00000015421    Tursiops truncatus  IFIT5   
ENSVPAG00000007869    Vicugna pacos  IFIT3   
ENSVPAG00000007871    Vicugna pacos  IFIT1   
ENSVPAG00000007868    Vicugna pacos  IFIT2   
ENSVPAG00000011508    Vicugna pacos  IFIT5   
ENSXETG00000021822    Xenopus tropicalis  IFIT1   
ENSXETG00000021818    Xenopus tropicalis  IFIT5   
ENSXETG00000015254  predicted Xenopus tropicalis  IFIT 
ENSXETG00000016292  predicted Xenopus tropicalis  IFIT 
ENSXETG00000021819  predicted Xenopus tropicalis  IFIT 
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Table 7 qRT-PCR Primer and Probe sequences 
 
Time post chicken IFN  stimulation (h)
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Figure 11-1 IFN alpha mRNA expression post IFN alpha stimulation 
Expression of IFNα and IFNλ mRNA in purified splenocytes from SPF chickens stimulated with 
500 ng/mL IFNα over the indicated time course. The bars represent the mean fold change of 
3 chicken spleens with the standard error of the mean (SEM) compared to the untreated 
sample, normalized against the housekeeping gene GAPDH. 
Target Gene Forward Primer Seq. Reverse Primer Seq. Reporter 1 Sequence
ch GAPDH CCCCAATGTCTCTGTTGTTGAC CAGCCTTCACTACCCTCTTGAT CTTGGCTGGTTTCTCC
ch IFNα GGACATGGCTCCCACACTAC TCCAGGATGGTGTCGTTGAAG CAGCGCGTCTTGCTC
ch IFNβ ACAACTTCCTACAGCACAACAACTA GCCTGGAGGCGGACATG TCCCAGGTACAAGCACTG
ch IFNλ CATCGGAAGTGGGACATAGCT CCTCCACCAGGGTGATTCG TCAGGTACCGACAGCTC
ch IFNλR1 GGATCTCCACCAGATGTGTTGTAC GGAACCTTTATCCATTTGTCCATACG CTGTGAGGTATGAAAGCAA
ch IL-10R2 CGCAAAGGCAACCTAAGTTATACTG TTGGTTGTCACATTGTTAAAATTCTGCTT CCAGGCCAAAAGCATT
ch ISG IFIT5 CAGAATTTAATGCCGGCTATGC TGCAAGTAAAGCCAAAAGATAAGTGT TCTGAAGCGTGCACTGAAACTGAATCCAA
ch ISG MX GTCCAAGAGGCTGAATAACAGAGAA GGTCGGATCTTTCTGTCATATTGGT CTGCTGCCTCATCCTT
ch ISG PKR GCAGAAGTAAGAGTGAGGCAAATGA GCCACCTTTACCAATAGGCTCTAT CTGTGGATGAAAGGTTTC
ch ISG Viperin CTGATCAGGGAACGGTGGTT ACGTTGACTTCCTCATTAAAACTATCACA CAAGAAGTATGGTGAATATTT
ch ISG ZAP AAATTGAAAAAGCCTATTGTGACCCAAA GGAGAGGGTCATTGTCTGGAAATT CTGCTGCACTGCTGTTT
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Figure 11-2 Alignment of th predicted and sequenced chicken IFIT5 sequence 
Gene Alignment of the sequenced (KT180229.1) and the predicted sequence of IFIT5.  
Numbers on at the end of each sequence indicates gene length. Red indicates conserved 
base pairs and black indicated a SNP. 
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Figure 11-3 in silico translated protein sequence alignment of the predicted and sequenced chicken IFIT5 sequence 
Protein alignment of the sequenced and in silico translated IFIT5(KT180229.1) and the 
predicted and translated sequence. Numbers on at the end of each sequence indicates 
protein length. Red indicates conserved amino acids and black indicated a SNP. 
 
